<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Environ Res Public Health</journal-id><journal-id journal-id-type="iso-abbrev">Int J Environ Res Public Health</journal-id><journal-id journal-id-type="publisher-id">ijerph</journal-id><journal-title-group><journal-title>International Journal of Environmental Research and Public Health</journal-title></journal-title-group><issn pub-type="ppub">1661-7827</issn><issn pub-type="epub">1660-4601</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7084951</article-id><article-id pub-id-type="doi">10.3390/ijerph17051686</article-id><article-id pub-id-type="publisher-id">ijerph-17-01686</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Su</surname><given-names>Shih-Bin</given-names></name><xref ref-type="aff" rid="af1-ijerph-17-01686">1</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Hsiao-Liang</given-names></name><xref ref-type="aff" rid="af2-ijerph-17-01686">2</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Kow-Tong</given-names></name><xref ref-type="aff" rid="af3-ijerph-17-01686">3</xref><xref ref-type="aff" rid="af4-ijerph-17-01686">4</xref><xref rid="c1-ijerph-17-01686" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-ijerph-17-01686"><label>1</label>Department of Occupational Medicine, Chi-Mei Medical Center, Tainan 710, Taiwan; <email>shihbin.su@msa.hinet.net</email></aff><aff id="af2-ijerph-17-01686"><label>2</label>Department of Surveillance, Centers for Disease Control, Taipei 100, Taiwan; <email>hlchang@cdc.gov.tw</email></aff><aff id="af3-ijerph-17-01686"><label>3</label>Department of Occupational Medicine, Tainan Municipal Hospital (managed by Show Chwan Medical Care Corporation), Tainan 701, Taiwan</aff><aff id="af4-ijerph-17-01686"><label>4</label>Department of Public Health, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan</aff><author-notes><corresp id="c1-ijerph-17-01686"><label>*</label>Correspondence: <email>ktchen@mail.ncku.edu.tw</email>; Tel.: +886-6-2609926; Fax: +886-6-2606351</corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2020</year></pub-date><volume>17</volume><issue>5</issue><elocation-id>1686</elocation-id><history><date date-type="received"><day>17</day><month>1</month><year>2020</year></date><date date-type="accepted"><day>29</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Mumps is an important childhood infectious disease caused by mumps virus (MuV). We reviewed the epidemiology, pathogenesis, and vaccine development of mumps. Previous studies were identified using the key words &#x0201c;mumps&#x0201d; and &#x0201c;epidemiology&#x0201d;, &#x0201c;pathogenesis&#x0201d; or &#x0201c;vaccine&#x0201d; in MEDLINE, PubMed, Embase, Web of Science, and Google Scholar. We excluded the articles that were not published in the English language, manuscripts without abstracts, and opinion articles from the review. The number of cases caused by MuV decreased steeply after the introduction of the mumps vaccine worldwide. In recent years, a global resurgence of mumps cases in developed countries and cases of aseptic meningitis caused by some mumps vaccine strains have renewed the importance of MuV infection worldwide. The performance of mumps vaccination has become an important issue for controlling mumps infections. Vaccine development and routine vaccination are still effective measures to globally reduce the incidence of mumps infections. During outbreaks, a third of MMR vaccine is recommended for groups of persons determined by public authorities.</p></abstract><kwd-group><kwd>mumps</kwd><kwd>epidemiology</kwd><kwd>pathogenesis</kwd><kwd>vaccine</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijerph-17-01686"><title>1. Introduction</title><p>Mumps is known as an important vaccine-preventable childhood viral disease [<xref rid="B1-ijerph-17-01686" ref-type="bibr">1</xref>]. The clinical pictures of mumps virus (MuV) infection is characterized by pain and swelling of the parotid glands, but can involve various other tissues and organs [<xref rid="B2-ijerph-17-01686" ref-type="bibr">2</xref>]. It can cause serious complications including encephalitis, meningitis, orchitis, myocarditis, pancreatitis, and nephritis [<xref rid="B2-ijerph-17-01686" ref-type="bibr">2</xref>,<xref rid="B3-ijerph-17-01686" ref-type="bibr">3</xref>]. Although mumps is a benign disease, often with complete recovery within a few weeks after being infected, long-term outcomes, such as seizures, cranial nerve palsies, hydrocephalus, and deafness, can occur [<xref rid="B3-ijerph-17-01686" ref-type="bibr">3</xref>,<xref rid="B4-ijerph-17-01686" ref-type="bibr">4</xref>]. Due to its benign clinical picture, mumps has been somewhat neglected compared with other infectious diseases (e.g., measles). However, in 2016 and 2017, the number of cases of mumps increased almost two-times compared to those reported in the previous five years in the United States (US) [<xref rid="B5-ijerph-17-01686" ref-type="bibr">5</xref>]. Additionally, in recent years, several huge outbreaks of the mumps infection have been reported in developed countries [<xref rid="B6-ijerph-17-01686" ref-type="bibr">6</xref>]. How to prevent and control the epidemic of mumps has sparked a new problem of public health. Previous report showed that 70% of patients with known vaccination history had received two doses of measles, mumps, and rubella (MMR) vaccine prior to illness [<xref rid="B5-ijerph-17-01686" ref-type="bibr">5</xref>]. Compared to mumps, cases of measles and rubella rarely occur in person with two doses of MMR vaccine, suggesting some factors of mumps vaccine influences its effectiveness [<xref rid="B3-ijerph-17-01686" ref-type="bibr">3</xref>]. Therefore, understanding the characteristics of MuV epidemiology, pathogenesis, and vaccine is important to protect against the spread of MuV infection. The purpose of this study was to summarize the epidemiology, pathogenesis, and vaccine of mumps and recommendations arising from this project.</p><p>All papers used in this review were published 2002 or later. These papers related to mumps virus infection were obtained by searching online database of MEDLINE (National Library of Medicine, Bethesda, MD, USA), PubMed, Embase, Web of Science, and Google Scholar using in combination of key terms &#x0201c;mumps&#x0201d; and &#x0201c;epidemiology&#x0201d;, &#x0201c;pathogenesis&#x0201d;, or &#x0201c;vaccine&#x0201d;. The articles for review were restricted to articles published in the English language. Additional sources were identified from the references of relevant literature. Articles without abstracts and opinion articles were excluded from the review. After selecting the articles, potential information related to epidemiology, pathogenesis, and vaccine of mumps were extracted and classified according to the categories of epidemiology, pathogenesis, and vaccines.</p><p>Searches of literatures were carried out in September and October 2019. A total of 3002 papers were identified from the study sources and this was reduced to 124 after screening the un-relevant articles and duplicates were removed (<xref ref-type="fig" rid="ijerph-17-01686-f001">Figure 1</xref>).</p></sec><sec id="sec2-ijerph-17-01686"><title>2. Epidemiology</title><p>Mumps was a serious disease that cause significant morbidity and mortality worldwide before the program of mumps vaccination starting [<xref rid="B5-ijerph-17-01686" ref-type="bibr">5</xref>]. In the pre-vaccine era, mumps was a severe contagious disease with a high morbidity of approximately 40&#x02013;726 cases per 100,000 population per year [<xref rid="B7-ijerph-17-01686" ref-type="bibr">7</xref>,<xref rid="B8-ijerph-17-01686" ref-type="bibr">8</xref>,<xref rid="B9-ijerph-17-01686" ref-type="bibr">9</xref>,<xref rid="B10-ijerph-17-01686" ref-type="bibr">10</xref>,<xref rid="B11-ijerph-17-01686" ref-type="bibr">11</xref>,<xref rid="B12-ijerph-17-01686" ref-type="bibr">12</xref>,<xref rid="B13-ijerph-17-01686" ref-type="bibr">13</xref>,<xref rid="B14-ijerph-17-01686" ref-type="bibr">14</xref>,<xref rid="B15-ijerph-17-01686" ref-type="bibr">15</xref>,<xref rid="B16-ijerph-17-01686" ref-type="bibr">16</xref>,<xref rid="B17-ijerph-17-01686" ref-type="bibr">17</xref>,<xref rid="B18-ijerph-17-01686" ref-type="bibr">18</xref>,<xref rid="B19-ijerph-17-01686" ref-type="bibr">19</xref>,<xref rid="B20-ijerph-17-01686" ref-type="bibr">20</xref>,<xref rid="B21-ijerph-17-01686" ref-type="bibr">21</xref>,<xref rid="B22-ijerph-17-01686" ref-type="bibr">22</xref>,<xref rid="B23-ijerph-17-01686" ref-type="bibr">23</xref>,<xref rid="B24-ijerph-17-01686" ref-type="bibr">24</xref>] (<xref rid="ijerph-17-01686-t001" ref-type="table">Table 1</xref>). During the pre-vaccine era, mumps was circulating endemically with a periodic spike of two to five years and a peak incidence of infection among children aged five to seven years old in several regions globally [<xref rid="B23-ijerph-17-01686" ref-type="bibr">23</xref>,<xref rid="B24-ijerph-17-01686" ref-type="bibr">24</xref>,<xref rid="B25-ijerph-17-01686" ref-type="bibr">25</xref>,<xref rid="B26-ijerph-17-01686" ref-type="bibr">26</xref>]. Mump infections frequently occurred in crowded population centers, e.g., prisons, kindergartens, boarding schools, military barracks, and other similar crowded settings [<xref rid="B22-ijerph-17-01686" ref-type="bibr">22</xref>]. Several risk factors have been reported in mumps infection including age, exposure, compromised immunity, time of year, travel, and vaccination status. Although there is no evidence of a difference on occurrence of MuV infections between the sexes, males seemly have higher risk to present complications [<xref rid="B22-ijerph-17-01686" ref-type="bibr">22</xref>,<xref rid="B23-ijerph-17-01686" ref-type="bibr">23</xref>]. Previous serosurvey studies were conducted in several countries prior to the introduction of vaccines [<xref rid="B21-ijerph-17-01686" ref-type="bibr">21</xref>,<xref rid="B27-ijerph-17-01686" ref-type="bibr">27</xref>,<xref rid="B28-ijerph-17-01686" ref-type="bibr">28</xref>,<xref rid="B29-ijerph-17-01686" ref-type="bibr">29</xref>]. They showed that 50% of children aged four to six years old and 90% of children aged 14&#x02013;15 years old were seropositive, with a steep increase in mumps antibody levels at two to three years of age. These results indicate that almost all individuals without receiving mumps vaccination will eventually become infected [<xref rid="B21-ijerph-17-01686" ref-type="bibr">21</xref>].</p><p>In the vaccine era, the widespread use of mumps vaccines has substantially reduced the risk of occurrence as well as the number of serious complications due to mumps [<xref rid="B1-ijerph-17-01686" ref-type="bibr">1</xref>,<xref rid="B20-ijerph-17-01686" ref-type="bibr">20</xref>]. The rate of mumps infection was greatly reduced after the introduction of mumps vaccination (<xref rid="ijerph-17-01686-t001" ref-type="table">Table 1</xref>). The epidemiologic pattern of mumps changing is based on the various vaccination program, such as the number of doses of vaccination, age at vaccination, and vaccine coverage. The coverage rate of mumps vaccination increases, the average age at infection increases until the level of seropositive population needed to stop spread of mumps has been achieved [<xref rid="B29-ijerph-17-01686" ref-type="bibr">29</xref>,<xref rid="B30-ijerph-17-01686" ref-type="bibr">30</xref>]. If vaccine coverage rate is insufficient, it can lead to an increase in the burden of severe sequelae as the disease shifts to older age groups in which mumps complications are more prevalent [<xref rid="B21-ijerph-17-01686" ref-type="bibr">21</xref>,<xref rid="B31-ijerph-17-01686" ref-type="bibr">31</xref>,<xref rid="B32-ijerph-17-01686" ref-type="bibr">32</xref>,<xref rid="B33-ijerph-17-01686" ref-type="bibr">33</xref>,<xref rid="B34-ijerph-17-01686" ref-type="bibr">34</xref>].</p><p>A variation in the peak season of mumps infections between different years has been reported in some studies. In temperate climate, the occurrences of MuV infections are strong seasonality, with peaks in winter and spring [<xref rid="B25-ijerph-17-01686" ref-type="bibr">25</xref>,<xref rid="B35-ijerph-17-01686" ref-type="bibr">35</xref>]. A higher risk for mumps infections was observed during the summer months than during other seasons in Asia, and epidemics recur with a seasonal pattern [<xref rid="B35-ijerph-17-01686" ref-type="bibr">35</xref>,<xref rid="B36-ijerph-17-01686" ref-type="bibr">36</xref>,<xref rid="B37-ijerph-17-01686" ref-type="bibr">37</xref>]. A previous study showed that the occurrence of MuV infection increased as temperature and humidity increased [<xref rid="B35-ijerph-17-01686" ref-type="bibr">35</xref>]. The reasons of the seasonal pattern of mumps infection may be due to the following factors: the fluctuations of human immune competence mediated by seasonal factors, such as levels of melatonin [<xref rid="B38-ijerph-17-01686" ref-type="bibr">38</xref>]; seasonality-related behavioral factors, such as school attendance and indoor crowding [<xref rid="B26-ijerph-17-01686" ref-type="bibr">26</xref>]; and meteorological factors [<xref rid="B36-ijerph-17-01686" ref-type="bibr">36</xref>,<xref rid="B37-ijerph-17-01686" ref-type="bibr">37</xref>,<xref rid="B39-ijerph-17-01686" ref-type="bibr">39</xref>], including temperature, sunshine, wind, and relative humidity. However, human behavioral factors alone do not explain the seasonal pattern observed for certain cases of mumps infection [<xref rid="B38-ijerph-17-01686" ref-type="bibr">38</xref>,<xref rid="B40-ijerph-17-01686" ref-type="bibr">40</xref>].</p><p>Although mumps was initially successfully controlled by vaccination in developed countries [<xref rid="B31-ijerph-17-01686" ref-type="bibr">31</xref>,<xref rid="B32-ijerph-17-01686" ref-type="bibr">32</xref>,<xref rid="B33-ijerph-17-01686" ref-type="bibr">33</xref>,<xref rid="B34-ijerph-17-01686" ref-type="bibr">34</xref>,<xref rid="B41-ijerph-17-01686" ref-type="bibr">41</xref>], sporadic mumps outbreaks began to occur globally [<xref rid="B42-ijerph-17-01686" ref-type="bibr">42</xref>,<xref rid="B43-ijerph-17-01686" ref-type="bibr">43</xref>,<xref rid="B44-ijerph-17-01686" ref-type="bibr">44</xref>,<xref rid="B45-ijerph-17-01686" ref-type="bibr">45</xref>,<xref rid="B46-ijerph-17-01686" ref-type="bibr">46</xref>,<xref rid="B47-ijerph-17-01686" ref-type="bibr">47</xref>,<xref rid="B48-ijerph-17-01686" ref-type="bibr">48</xref>,<xref rid="B49-ijerph-17-01686" ref-type="bibr">49</xref>]. During recent years, outbreaks of MuV infections have occurred in adolescent populations, many of whom had been vaccinated with mumps vaccines previously, in the USA [<xref rid="B46-ijerph-17-01686" ref-type="bibr">46</xref>,<xref rid="B50-ijerph-17-01686" ref-type="bibr">50</xref>], Canada [<xref rid="B42-ijerph-17-01686" ref-type="bibr">42</xref>], Australia [<xref rid="B49-ijerph-17-01686" ref-type="bibr">49</xref>,<xref rid="B51-ijerph-17-01686" ref-type="bibr">51</xref>], United Kingdom [<xref rid="B34-ijerph-17-01686" ref-type="bibr">34</xref>,<xref rid="B48-ijerph-17-01686" ref-type="bibr">48</xref>], and France [<xref rid="B14-ijerph-17-01686" ref-type="bibr">14</xref>,<xref rid="B47-ijerph-17-01686" ref-type="bibr">47</xref>]. Several reasons were raised to explain the unexpected occurrence: waning immunity [<xref rid="B52-ijerph-17-01686" ref-type="bibr">52</xref>,<xref rid="B53-ijerph-17-01686" ref-type="bibr">53</xref>]; the efficacy of mumps vaccine, which has varied according to the doses of vaccinations and different virus strain used for production of the mumps vaccine [<xref rid="B54-ijerph-17-01686" ref-type="bibr">54</xref>,<xref rid="B55-ijerph-17-01686" ref-type="bibr">55</xref>,<xref rid="B56-ijerph-17-01686" ref-type="bibr">56</xref>,<xref rid="B57-ijerph-17-01686" ref-type="bibr">57</xref>]; and how much the level of antibody persisted in body with time after vaccination or natural infection among population [<xref rid="B24-ijerph-17-01686" ref-type="bibr">24</xref>,<xref rid="B43-ijerph-17-01686" ref-type="bibr">43</xref>].</p></sec><sec id="sec3-ijerph-17-01686"><title>3. Pathogenesis</title><p>Both mumps and parainfluenza virus belong to the paramyxovirus group and are antigenically related. It has been reported that parainfluenza virus has been isolated from cases of parotitis infection [<xref rid="B39-ijerph-17-01686" ref-type="bibr">39</xref>] and MuV has been isolated from patients with upper respiratory infection without inflammation of salivary gland [<xref rid="B58-ijerph-17-01686" ref-type="bibr">58</xref>]. Paramyxoviridae is an enveloped particle containing a non-segmented negative strand RNA molecule of 15,384 nucleotides [<xref rid="B40-ijerph-17-01686" ref-type="bibr">40</xref>]. The mumps virus is antigenically stable and does not exhibit great shifts in ways such as influenza virus. The incubation period for mumps ranges from 12&#x02013;25 days post exposure and parotitis typically occurs 16&#x02013;18 days after exposure [<xref rid="B2-ijerph-17-01686" ref-type="bibr">2</xref>]. There are at least 12 genotypes which are defined based on the sequence of the small hydrophobic (SH) gene [<xref rid="B59-ijerph-17-01686" ref-type="bibr">59</xref>]. Currently, the most frequently detected mumps genotype in recent outbreaks worldwide is genotype G [<xref rid="B60-ijerph-17-01686" ref-type="bibr">60</xref>].</p><p>MuV is transmitted to people by respiratory or oral route with infected respiratory droplets or secretions and the incubation time ranges from two to four weeks [<xref rid="B61-ijerph-17-01686" ref-type="bibr">61</xref>]. The virus has been isolated from saliva from seven days before until eight days after the occurrence of clinical symptoms [<xref rid="B62-ijerph-17-01686" ref-type="bibr">62</xref>]. Following exposure, MuV infects the upper respiratory tract via binding to sialic acid to enter polarized epithelial cells in the respiratory tract and enhance the invasion of mumps virus to neighboring cells [<xref rid="B63-ijerph-17-01686" ref-type="bibr">63</xref>]. MuV is markedly secreted from the epithelial cells, which causes virus growth in the glandular epithelium and shedding of mumps virus in saliva [<xref rid="B63-ijerph-17-01686" ref-type="bibr">63</xref>]. MuV can spread systemically in human body resulting in viremia during the early phase of infection [<xref rid="B64-ijerph-17-01686" ref-type="bibr">64</xref>]. Humans are known as the only natural host of MuV. Most (approximately one-half) cases are asymptomatic or suffer from only mild respiratory symptoms or fever after MuV infections [<xref rid="B65-ijerph-17-01686" ref-type="bibr">65</xref>]. Classic mumps infection is characterized by parotitis, but inflammation of salivary gland is not a main or necessary clinical manifestation of mumps infection [<xref rid="B66-ijerph-17-01686" ref-type="bibr">66</xref>]. Other organs, including the central nervous system (CNS) [<xref rid="B67-ijerph-17-01686" ref-type="bibr">67</xref>], heart, kidney [<xref rid="B68-ijerph-17-01686" ref-type="bibr">68</xref>], and genital organs [<xref rid="B69-ijerph-17-01686" ref-type="bibr">69</xref>] can also be affected via viremia dissemination. Viremia seems to be inhibited by the humoral antibodies and the virus level in salivary secretion correlates inversely with the local level of virus-specific secretory IgA produced [<xref rid="B70-ijerph-17-01686" ref-type="bibr">70</xref>]. It was hypothesized that neutralizing antibody that is produced in salivary glands may play an important role in restricting the replication of mumps virus and its excretion into saliva. In addition, the level of T cell antibody may play a role in the inhibition and clearance of mumps virus. It has been assumed that mumps virus invades T cells and efficiently grows in these cells [<xref rid="B71-ijerph-17-01686" ref-type="bibr">71</xref>]. Migrating mumps virus-infected T cells could enhance the mumps virus to disseminate to the various organs and might therefore play a key role in the development of mumps disease [<xref rid="B71-ijerph-17-01686" ref-type="bibr">71</xref>].</p></sec><sec id="sec4-ijerph-17-01686"><title>4. Mumps Vaccines</title><sec id="sec4dot1-ijerph-17-01686"><title>4.1. General Considerations</title><p>The first inactivated mumps vaccine was developed and used in the USA in 1950 [<xref rid="B1-ijerph-17-01686" ref-type="bibr">1</xref>]. Until the 1960s, live attenuated mumps virus vaccines were first used in the USA and Soviet Union [<xref rid="B2-ijerph-17-01686" ref-type="bibr">2</xref>,<xref rid="B72-ijerph-17-01686" ref-type="bibr">72</xref>]. They used different virus strains to develop mumps vaccines. The USA used the Jerry Lynn vaccine strain, whereas the Soviet Union used a different strain called the Leningrad-3 strain. Additionally, several other virus strains, such as Rubini, Urabe, RIT 4385, Leningrad-Zagreb (L-Z), Miyahara, Hoshino, Tori, NK M-46, and S-12, have been used worldwide to produce mumps vaccines [<xref rid="B59-ijerph-17-01686" ref-type="bibr">59</xref>,<xref rid="B72-ijerph-17-01686" ref-type="bibr">72</xref>].</p><p>The Jeryl Lynn and Urabe Am9 strains have been the most popularly used in the world, followed by the Leningrad-Zagreb, Leningrad-3, and Rubini strains. The newer RIT 4385 strain was derived from the Jeryl Lynn strain [<xref rid="B21-ijerph-17-01686" ref-type="bibr">21</xref>,<xref rid="B72-ijerph-17-01686" ref-type="bibr">72</xref>,<xref rid="B73-ijerph-17-01686" ref-type="bibr">73</xref>,<xref rid="B74-ijerph-17-01686" ref-type="bibr">74</xref>,<xref rid="B75-ijerph-17-01686" ref-type="bibr">75</xref>]. Initially, mumps vaccines (panel) were produced as a form of monovalent vaccine, and mumps vaccines are currently manufactured as a component of the trivalent measles-mumps-rubella (MMR) vaccine worldwide [<xref rid="B73-ijerph-17-01686" ref-type="bibr">73</xref>]. At least five known combination MMR vaccines have been developed since the 1960s worldwide (<xref rid="ijerph-17-01686-t002" ref-type="table">Table 2</xref>) [<xref rid="B72-ijerph-17-01686" ref-type="bibr">72</xref>,<xref rid="B73-ijerph-17-01686" ref-type="bibr">73</xref>,<xref rid="B74-ijerph-17-01686" ref-type="bibr">74</xref>,<xref rid="B75-ijerph-17-01686" ref-type="bibr">75</xref>,<xref rid="B76-ijerph-17-01686" ref-type="bibr">76</xref>]. To date, the MMR vaccine has been used in more than 120 countries worldwide [<xref rid="B2-ijerph-17-01686" ref-type="bibr">2</xref>,<xref rid="B76-ijerph-17-01686" ref-type="bibr">76</xref>]. Since the mid-2000s, there are two measles-mumps-rubella-varicella (MMRV) vaccines available: ProQuad (Merck and Co. Inc. West Point, PA, USA), and Priorix-Tetra (GlaxoSmithKline Biologicals, Rixensart, Belgium) (<xref rid="ijerph-17-01686-t003" ref-type="table">Table 3</xref>) [<xref rid="B76-ijerph-17-01686" ref-type="bibr">76</xref>,<xref rid="B77-ijerph-17-01686" ref-type="bibr">77</xref>,<xref rid="B78-ijerph-17-01686" ref-type="bibr">78</xref>]. Vaccination against MMR or MMRV has recently been conducted mainly with combination vaccines.</p></sec><sec id="sec4dot2-ijerph-17-01686"><title>4.2. Jeryl Lynn Strain Mumps Vaccine</title><p>The Jeryl Lynn strain, named after a woman who developed mumps with unilateral parotitis in 1963, was the first vaccine strain to be produced in the USA by passaging the virus in embryonated hen eggs and chicken embryo fibroblast cultures [<xref rid="B76-ijerph-17-01686" ref-type="bibr">76</xref>,<xref rid="B79-ijerph-17-01686" ref-type="bibr">79</xref>,<xref rid="B80-ijerph-17-01686" ref-type="bibr">80</xref>,<xref rid="B81-ijerph-17-01686" ref-type="bibr">81</xref>]. The strain was licensed in the USA in 1967 and since then a live attenuated Jeryl Lynn vaccine has been used in many countries [<xref rid="B82-ijerph-17-01686" ref-type="bibr">82</xref>]. Another mumps vaccine, the RIT 4385 strain, was developed from a single Jeryl Lynn clone by passage through chick embryo fibroblast cultures [<xref rid="B83-ijerph-17-01686" ref-type="bibr">83</xref>]. A clinical study conducted in an industrialized country found that the seroconversion rates after vaccination with a single dose of the Jeryl Lynn strain mumps vaccine were 80%&#x02013;100% [<xref rid="B84-ijerph-17-01686" ref-type="bibr">84</xref>]. Several studies have presented existence of antibodies in a high ratio of vaccinated populations. In Sweden, 73% (<italic>n</italic> = 167) children who vaccinated with one dose of MMR vaccine (containing the Jeryl Lynn strain) at 18 months of age persisted to be seropositive at time of vaccination 12 years later, and 93% were seropositive after a second dose of mumps vaccination [<xref rid="B85-ijerph-17-01686" ref-type="bibr">85</xref>]. In Finland [<xref rid="B86-ijerph-17-01686" ref-type="bibr">86</xref>], a 9-year serological follow-up period was performed among 254 children. Among these children, one dose of MMR vaccine (containing the Jeryl Lynn mumps strain) was given to children at the ages of 14&#x02013;18 months and six years. The seroconversion rate was 86% among the vaccinated children, and the seropositivity rate was 95% after revaccination. These results indicated that a two-dose MMR vaccination resulted in a high mumps immunity level. In the Dominican Republic [<xref rid="B87-ijerph-17-01686" ref-type="bibr">87</xref>], a clinical evaluation of a new measles (Schwarz strain), mumps (Jeryl Lynn strain), and rubella (Cendehill strain) combined live vaccine was conducted. In this study, there were more than 900 study children with a 94% seroconversion rate for mumps vaccines among the study children aged one to six years [<xref rid="B87-ijerph-17-01686" ref-type="bibr">87</xref>]. It was found that the occurrence of mumps increased with time elapse since vaccination in the epidemic of mumps in USA, suggesting waning of immunity is likely to play a role [<xref rid="B88-ijerph-17-01686" ref-type="bibr">88</xref>,<xref rid="B89-ijerph-17-01686" ref-type="bibr">89</xref>].</p><p>The Jeryl Lynn strain, named after a woman who developed mumps with unilateral parotitis in 1963, was the first vaccine strain to be produced in the USA by passaging the virus in embryonated hen eggs and chicken embryo fibroblast cultures [<xref rid="B76-ijerph-17-01686" ref-type="bibr">76</xref>,<xref rid="B79-ijerph-17-01686" ref-type="bibr">79</xref>,<xref rid="B80-ijerph-17-01686" ref-type="bibr">80</xref>,<xref rid="B81-ijerph-17-01686" ref-type="bibr">81</xref>]. The strain was licensed in the USA in 1967 and since then a live attenuated Jeryl Lynn vaccine has been used in many countries [<xref rid="B82-ijerph-17-01686" ref-type="bibr">82</xref>]. Another mumps vaccine, the RIT 4385 strain, was developed from a single Jeryl Lynn clone by passage through chick embryo fibroblast cultures [<xref rid="B83-ijerph-17-01686" ref-type="bibr">83</xref>]. A clinical study conducted in an industrialized country found that the seroconversion rates after vaccination with a single dose of the Jeryl Lynn strain mumps vaccine were 80%&#x02013;100% [<xref rid="B84-ijerph-17-01686" ref-type="bibr">84</xref>]. Several studies have presented existence of antibodies in a high ratio of vaccinated populations. In Sweden, 73% (<italic>n</italic> = 167) children who vaccinated with one dose of MMR vaccine (containing the Jeryl Lynn strain) at 18 months of age persisted to be seropositive at time of vaccination 12 years later, and 93% were seropositive after a second dose of mumps vaccination [<xref rid="B85-ijerph-17-01686" ref-type="bibr">85</xref>]. In Finland [<xref rid="B86-ijerph-17-01686" ref-type="bibr">86</xref>], a 9-year serological follow-up period was performed among 254 children. Among these children, one dose of MMR vaccine (containing the Jeryl Lynn mumps strain) was given to children at the ages of 14&#x02013;18 months and six years. The seroconversion rate was 86% among the vaccinated children, and the seropositivity rate was 95% after revaccination. These results indicated that a two-dose MMR vaccination resulted in a high mumps immunity level. In the Dominican Republic [<xref rid="B87-ijerph-17-01686" ref-type="bibr">87</xref>], a clinical evaluation of a new measles (Schwarz strain), mumps (Jeryl Lynn strain), and rubella (Cendehill strain) combined live vaccine was conducted. In this study, there were more than 900 study children with a 94% seroconversion rate for mumps vaccines among the study children aged one to six years [<xref rid="B87-ijerph-17-01686" ref-type="bibr">87</xref>]. It was found that the occurrence of mumps increased with time elapse since vaccination in the epidemic of mumps in USA, suggesting waning of immunity is likely to play a role [<xref rid="B88-ijerph-17-01686" ref-type="bibr">88</xref>,<xref rid="B89-ijerph-17-01686" ref-type="bibr">89</xref>].</p><p>The Jeryl Lynn strain, named after a woman who developed mumps with unilateral parotitis in 1963, was the first vaccine strain to be produced in the USA by passaging the virus in embryonated hen eggs and chicken embryo fibroblast cultures [<xref rid="B76-ijerph-17-01686" ref-type="bibr">76</xref>,<xref rid="B79-ijerph-17-01686" ref-type="bibr">79</xref>,<xref rid="B80-ijerph-17-01686" ref-type="bibr">80</xref>,<xref rid="B81-ijerph-17-01686" ref-type="bibr">81</xref>]. The strain was licensed in the USA in 1967 and since then a live attenuated Jeryl Lynn vaccine has been used in many countries [<xref rid="B82-ijerph-17-01686" ref-type="bibr">82</xref>]. Another mumps vaccine, the RIT 4385 strain, was developed from a single Jeryl Lynn clone by passage through chick embryo fibroblast cultures [<xref rid="B83-ijerph-17-01686" ref-type="bibr">83</xref>]. A clinical study conducted in an industrialized country found that the seroconversion rates after vaccination with a single dose of the Jeryl Lynn strain mumps vaccine were 80%&#x02013;100% [<xref rid="B84-ijerph-17-01686" ref-type="bibr">84</xref>]. Several studies have presented existence of antibodies in a high ratio of vaccinated populations. In Sweden, 73% (<italic>n</italic> = 167) children who vaccinated with one dose of MMR vaccine (containing the Jeryl Lynn strain) at 18 months of age persisted to be seropositive at time of vaccination 12 years later, and 93% were seropositive after a second dose of mumps vaccination [<xref rid="B85-ijerph-17-01686" ref-type="bibr">85</xref>]. In Finland [<xref rid="B86-ijerph-17-01686" ref-type="bibr">86</xref>], a 9-year serological follow-up period was performed among 254 children. Among these children, one dose of MMR vaccine (containing the Jeryl Lynn mumps strain) was given to children at the ages of 14&#x02013;18 months and six years. The seroconversion rate was 86% among the vaccinated children, and the seropositivity rate was 95% after revaccination. These results indicated that a two-dose MMR vaccination resulted in a high mumps immunity level. In the Dominican Republic [<xref rid="B87-ijerph-17-01686" ref-type="bibr">87</xref>], a clinical evaluation of a new measles (Schwarz strain), mumps (Jeryl Lynn strain), and rubella (Cendehill strain) combined live vaccine was conducted. In this study, there were more than 900 study children with a 94% seroconversion rate for mumps vaccines among the study children aged one to six years [<xref rid="B87-ijerph-17-01686" ref-type="bibr">87</xref>]. It was found that the occurrence of mumps increased with time elapse since vaccination in the epidemic of mumps in USA, suggesting waning of immunity is likely to play a role [<xref rid="B88-ijerph-17-01686" ref-type="bibr">88</xref>,<xref rid="B89-ijerph-17-01686" ref-type="bibr">89</xref>].</p><p>The Jeryl Lynn strain, named after a woman who developed mumps with unilateral parotitis in 1963, was the first vaccine strain to be produced in the USA by passaging the virus in embryonated hen eggs and chicken embryo fibroblast cultures [<xref rid="B76-ijerph-17-01686" ref-type="bibr">76</xref>,<xref rid="B79-ijerph-17-01686" ref-type="bibr">79</xref>,<xref rid="B80-ijerph-17-01686" ref-type="bibr">80</xref>,<xref rid="B81-ijerph-17-01686" ref-type="bibr">81</xref>]. The strain was licensed in the USA in 1967 and since then a live attenuated Jeryl Lynn vaccine has been used in many countries [<xref rid="B82-ijerph-17-01686" ref-type="bibr">82</xref>]. Another mumps vaccine, the RIT 4385 strain, was developed from a single Jeryl Lynn clone by passage through chick embryo fibroblast cultures [<xref rid="B83-ijerph-17-01686" ref-type="bibr">83</xref>]. A clinical study conducted in an industrialized country found that the seroconversion rates after vaccination with a single dose of the Jeryl Lynn strain mumps vaccine were 80%&#x02013;100% [<xref rid="B84-ijerph-17-01686" ref-type="bibr">84</xref>]. Several studies have presented existence of antibodies in a high ratio of vaccinated populations. In Sweden, 73% (<italic>n</italic> = 167) children who vaccinated with one dose of MMR vaccine (containing the Jeryl Lynn strain) at 18 months of age persisted to be seropositive at time of vaccination 12 years later, and 93% were seropositive after a second dose of mumps vaccination [<xref rid="B85-ijerph-17-01686" ref-type="bibr">85</xref>]. In Finland [<xref rid="B86-ijerph-17-01686" ref-type="bibr">86</xref>], a 9-year serological follow-up period was performed among 254 children. Among these children, one dose of MMR vaccine (containing the Jeryl Lynn mumps strain) was given to children at the ages of 14&#x02013;18 months and six years. The seroconversion rate was 86% among the vaccinated children, and the seropositivity rate was 95% after revaccination. These results indicated that a two-dose MMR vaccination resulted in a high mumps immunity level. In the Dominican Republic [<xref rid="B87-ijerph-17-01686" ref-type="bibr">87</xref>], a clinical evaluation of a new measles (Schwarz strain), mumps (Jeryl Lynn strain), and rubella (Cendehill strain) combined live vaccine was conducted. In this study, there were more than 900 study children with a 94% seroconversion rate for mumps vaccines among the study children aged one to six years [<xref rid="B87-ijerph-17-01686" ref-type="bibr">87</xref>]. It was found that the occurrence of mumps increased with time elapse since vaccination in the epidemic of mumps in USA, suggesting waning of immunity is likely to play a role [<xref rid="B88-ijerph-17-01686" ref-type="bibr">88</xref>,<xref rid="B89-ijerph-17-01686" ref-type="bibr">89</xref>].</p><p>The Jeryl Lynn strain, named after a woman who developed mumps with unilateral parotitis in 1963, was the first vaccine strain to be produced in the USA by passaging the virus in embryonated hen eggs and chicken embryo fibroblast cultures [<xref rid="B76-ijerph-17-01686" ref-type="bibr">76</xref>,<xref rid="B79-ijerph-17-01686" ref-type="bibr">79</xref>,<xref rid="B80-ijerph-17-01686" ref-type="bibr">80</xref>,<xref rid="B81-ijerph-17-01686" ref-type="bibr">81</xref>]. The strain was licensed in the USA in 1967 and since then a live attenuated Jeryl Lynn vaccine has been used in many countries [<xref rid="B82-ijerph-17-01686" ref-type="bibr">82</xref>]. Another mumps vaccine, the RIT 4385 strain, was developed from a single Jeryl Lynn clone by passage through chick embryo fibroblast cultures [<xref rid="B83-ijerph-17-01686" ref-type="bibr">83</xref>]. A clinical study conducted in an industrialized country found that the seroconversion rates after vaccination with a single dose of the Jeryl Lynn strain mumps vaccine were 80%&#x02013;100% [<xref rid="B84-ijerph-17-01686" ref-type="bibr">84</xref>]. Several studies have presented existence of antibodies in a high ratio of vaccinated populations. In Sweden, 73% (<italic>n</italic> = 167) children who vaccinated with one dose of MMR vaccine (containing the Jeryl Lynn strain) at 18 months of age persisted to be seropositive at time of vaccination 12 years later, and 93% were seropositive after a second dose of mumps vaccination [<xref rid="B85-ijerph-17-01686" ref-type="bibr">85</xref>]. In Finland [<xref rid="B86-ijerph-17-01686" ref-type="bibr">86</xref>], a 9-year serological follow-up period was performed among 254 children. Among these children, one dose of MMR vaccine (containing the Jeryl Lynn mumps strain) was given to children at the ages of 14&#x02013;18 months and six years. The seroconversion rate was 86% among the vaccinated children, and the seropositivity rate was 95% after revaccination. These results indicated that a two-dose MMR vaccination resulted in a high mumps immunity level. In the Dominican Republic [<xref rid="B87-ijerph-17-01686" ref-type="bibr">87</xref>], a clinical evaluation of a new measles (Schwarz strain), mumps (Jeryl Lynn strain), and rubella (Cendehill strain) combined live vaccine was conducted. In this study, there were more than 900 study children with a 94% seroconversion rate for mumps vaccines among the study children aged one to six years [<xref rid="B87-ijerph-17-01686" ref-type="bibr">87</xref>]. It was found that the occurrence of mumps increased with time elapse since vaccination in the epidemic of mumps in USA, suggesting waning of immunity is likely to play a role [<xref rid="B88-ijerph-17-01686" ref-type="bibr">88</xref>,<xref rid="B89-ijerph-17-01686" ref-type="bibr">89</xref>].</p><p>Natural mumps infection has been considered to give life-long immunity. However, the duration of vaccine-induced immunity has not been well documented, but detectable specific mumps virus-neutralizing antibodies correlate with resistance to clinical infection [<xref rid="B90-ijerph-17-01686" ref-type="bibr">90</xref>]. It has been found that the efficacy of the mumps vaccine containing the Jeryl Lynn strain was 95&#x02013;96% [<xref rid="B90-ijerph-17-01686" ref-type="bibr">90</xref>]. The effectiveness of two doses of MMR immunization is not as high as expected, and outbreaks have been reported in countries with high vaccine coverage [<xref rid="B91-ijerph-17-01686" ref-type="bibr">91</xref>,<xref rid="B92-ijerph-17-01686" ref-type="bibr">92</xref>,<xref rid="B93-ijerph-17-01686" ref-type="bibr">93</xref>]. It was reported that the estimated vaccine effectiveness for one-dose MMR vaccination was 85.4% (95% CI: 67.3&#x02013;93.4%), and that for two-dose MMR vaccination was 88.5% (95% CI: 78.1&#x02013;93.9%) in a study in Spain [<xref rid="B94-ijerph-17-01686" ref-type="bibr">94</xref>].</p><p>There was a study with a 10-year retrospective study of hospitalized cases of mumps in the USA that did not find an increased risk of aseptic meningitis after MMR containing the Jeryl Lynn strain of mumps (odds ratio &#x0003c;1.0 for all analyses) [<xref rid="B95-ijerph-17-01686" ref-type="bibr">95</xref>].</p><p>Since the mid-2000s, measles-mumps-rubella-varicella (MMRV) vaccines have been available [<xref rid="B96-ijerph-17-01686" ref-type="bibr">96</xref>]. The MMRV vaccine was developed based on the existing MMR and varicella vaccines. Licensed ProQuad (Merck and Co., Inc. West Point, PA, USA; Merk) and Priorix-Tetra (GlaxoSmithKline Biologicals, Rixensart, Belgium; GSK) have different measles virus strains (Edmonston strain and Schwarz strain, respectively), different mumps virus strains (RIT 4385 strain and Jeryl Lynn strain, respectively), the same rubella virus strain (Wistar RA 27/3 strain), and the same varicella virus strain (Oka strain) [<xref rid="B97-ijerph-17-01686" ref-type="bibr">97</xref>]. The RIT 4385 strain was developed by cloning a major population of the Jeryl Lynn strain [<xref rid="B98-ijerph-17-01686" ref-type="bibr">98</xref>,<xref rid="B99-ijerph-17-01686" ref-type="bibr">99</xref>]. Similar seroconversion rates of these four viruses were found between comparison groups [<xref rid="B59-ijerph-17-01686" ref-type="bibr">59</xref>,<xref rid="B79-ijerph-17-01686" ref-type="bibr">79</xref>]. Recent evidence has shown that the MMRV vaccines have comparable immunogenicity and safety profiles in healthy children [<xref rid="B97-ijerph-17-01686" ref-type="bibr">97</xref>]. The Jeryl Lynn mumps genotype A strain has been used in the MMR vaccine throughout the world. It shows a markedly lower incidence of aseptic meningitis than other strains and higher immune response [<xref rid="B79-ijerph-17-01686" ref-type="bibr">79</xref>].</p></sec><sec id="sec4dot3-ijerph-17-01686"><title>4.3. Leningrad-3 Strain Mumps Vaccine</title><p>The Leningrad-3 mumps attenuated strain was produced in the Soviet Union using the various strains obtained after 16 serial passages in guinea pig kidney tissue culture, and then further passages in Japanese quail embryo cultures [<xref rid="B100-ijerph-17-01686" ref-type="bibr">100</xref>]. Since 1974, vaccines (containing Leningrad-3 strain) have been used in the former Soviet Union. It is estimated that 8&#x02013;11 million doses of the Leningrad-3 mumps vaccine is produced every year [<xref rid="B78-ijerph-17-01686" ref-type="bibr">78</xref>]. There was a study to explore the seroconversion rates after vaccination with an MMR vaccine (measles vaccine with the Leningrad-16 strain, mumps vaccine with the Leningrad-3 strain, and rubella virus vaccine with the Leningrad-8 strain) [<xref rid="B100-ijerph-17-01686" ref-type="bibr">100</xref>]. This study showed that the mumps seroconversion rate was 89%&#x02013;98% and that there was a protective efficacy of 92%&#x02013;99% after vaccination with the MMR vaccine among the study children aged between one and seven years [<xref rid="B100-ijerph-17-01686" ref-type="bibr">100</xref>]. During 1979&#x02013;1986, there was a retrospective study to review medical records in the Slovenian population [<xref rid="B101-ijerph-17-01686" ref-type="bibr">101</xref>]. It was found the occurrence of aseptic meningitis was 100 cases per 100,000 doses of measles-mumps vaccine (containing the Leningrad-3 mumps strain), however, all patients with aseptic meningitis recovered with no sequelae [<xref rid="B101-ijerph-17-01686" ref-type="bibr">101</xref>].</p></sec><sec id="sec4dot4-ijerph-17-01686"><title>4.4. Leningrad-3-Zagreb Strain Mumps Vaccine</title><p>In Croatia and India, the Leningrad-3-Zagreb (L-Zagreb) strain was developed by further passage of the Leningrad-3 mumps virus by adaptation in chick embryo fibroblast cell culture [<xref rid="B79-ijerph-17-01686" ref-type="bibr">79</xref>,<xref rid="B102-ijerph-17-01686" ref-type="bibr">102</xref>]. The L-Zagreb strain has been used to prepare mumps vaccines. Between 1976 and 1987, it was estimated that over 10 million doses of the L-Zagreb mumps vaccine were used in the former Yugoslavia and elsewhere [<xref rid="B102-ijerph-17-01686" ref-type="bibr">102</xref>]. A study showed that the positive rate of IgG levels four weeks after immunization rose from 12% to 92% for mumps, with a vaccine efficacy of 97%&#x02013;100% [<xref rid="B103-ijerph-17-01686" ref-type="bibr">103</xref>]. Only mild side effects, including pain and swelling in 37 (4.3%) cases, mild fever in 51 (5.9%) cases, cough in 40 (4.6%) cases, and a transient rash in seven (0.8%) cases, were observed [<xref rid="B103-ijerph-17-01686" ref-type="bibr">103</xref>]. In Croatia, there were 90 cases of aseptic meningitis per 100,000 doses of MMR vaccine containing the L-Zagreb mumps strain between 1988 and 1992 [<xref rid="B104-ijerph-17-01686" ref-type="bibr">104</xref>]; this finding is similar to the finding reported by Cizman et al. (10 per 10,000) [<xref rid="B101-ijerph-17-01686" ref-type="bibr">101</xref>].</p></sec><sec id="sec4dot5-ijerph-17-01686"><title>4.5. Rubini Strain Mumps Vaccine</title><p>The Rubini strain was derived from a child of the same name presenting typical clinical signs and symptoms of mumps infection. A live attenuated mumps vaccine virus strain for human diploid cells was developed at the Swiss Serum and Vaccine Institute, Berne [<xref rid="B105-ijerph-17-01686" ref-type="bibr">105</xref>]. Attenuation of the wild virus was performed by isolation and serial passage in WI-38 human diploid cells, specific pathogen-free hen eggs and MRC-5 human diploid cells [<xref rid="B105-ijerph-17-01686" ref-type="bibr">105</xref>]. A mumps vaccine containing the Rubini strain was approved and commercialized in Switzerland in 1985, and over four million people worldwide had received this vaccine by 1990, [<xref rid="B74-ijerph-17-01686" ref-type="bibr">74</xref>].</p><p>In Germany, children aged 14&#x02013;24 months who received one dose of the MMR vaccine was conducted to explore the immunity response [<xref rid="B106-ijerph-17-01686" ref-type="bibr">106</xref>]. This study found that the seroconversion rate was 95% among children who received the Triviraten vaccine (containing the Rubini mumps strain), whereas the seroconversion rate was 100% when the mumps strain was Jeryl Lynn [<xref rid="B106-ijerph-17-01686" ref-type="bibr">106</xref>]. In Switzerland, a study was conducted to explore the secondary attack rates among family contacts and confirmed mumps case contacts [<xref rid="B106-ijerph-17-01686" ref-type="bibr">106</xref>]. It found a protective efficacy among persons vaccinated with mumps vaccine (containing the Rubini strain) was 6%, whereas the protective efficacy among persons vaccinated with mumps vaccine (containing the Urabe strain) was of 73%, and the persons vaccinated with mumps vaccine (containing Jeryl Lynn strain) was 62% [<xref rid="B107-ijerph-17-01686" ref-type="bibr">107</xref>]. In Italy, a case&#x02013;control study was performed between 1995 and 1996 [<xref rid="B108-ijerph-17-01686" ref-type="bibr">108</xref>]. This study showed the children vaccinated with the Rubini strain mumps vaccine had a higher risk of MuV infection, compared with children vaccinated with a Jeryl Lynn or Urabe strain mumps vaccine [<xref rid="B108-ijerph-17-01686" ref-type="bibr">108</xref>]. A case-cohort study comparing the effectiveness of vaccination with the Rubini strain to vaccination with the Jeryl Lynn strain vaccine was performed in Switzerland [<xref rid="B109-ijerph-17-01686" ref-type="bibr">109</xref>]. The effectiveness of vaccination with the Rubini strain was zero and that with the Jeryl Lynn strain was 70% against clinical mumps [<xref rid="B109-ijerph-17-01686" ref-type="bibr">109</xref>].</p></sec><sec id="sec4dot6-ijerph-17-01686"><title>4.6. Urabe Strain Mumps Vaccine</title><p>The Biken Institute in Japan developed the Urabe Am9 strain vaccine from mumps virus isolated from the saliva of a patient in 1979, and thereafter, the vaccine was licensed in Belgium, France, Italy, and many countries worldwide [<xref rid="B76-ijerph-17-01686" ref-type="bibr">76</xref>,<xref rid="B78-ijerph-17-01686" ref-type="bibr">78</xref>].</p><p>The Urabe Am9 strain was evaluated in children 14 to 20 months of age in a comparative trial with the Jeryl Lynn strain [<xref rid="B106-ijerph-17-01686" ref-type="bibr">106</xref>]. The seroconversion rates at six weeks, as detected with either one or two tests, were 94.8% after the Urabe Am9 strain and 96.7% after the Jeryl Lynn vaccine. Only mild infrequent adverse reactions were observed. Both strains of live attenuated mumps vaccine were immunogenic and well tolerated in this age group.</p><p>There was a study in Finland [<xref rid="B106-ijerph-17-01686" ref-type="bibr">106</xref>], in which the children who received a mumps vaccine at 14&#x02013;20 months of age. This study found the seroconversion rate after vaccination with a Urabe strain vaccine was 95%, compared with seroconversion rate of 97% among children vaccinated with the Jeryl Lynn strain [<xref rid="B106-ijerph-17-01686" ref-type="bibr">106</xref>]. According to the information obtaining from an outbreak investigation of mumps in an Asian population in Singapore [<xref rid="B107-ijerph-17-01686" ref-type="bibr">107</xref>], the vaccine efficacies of the Jeryl Lynn strain, Urabe strain and Rubini strain mumps vaccines were 81%, 54%, and 55%, respectively.</p><p>The immune response after vaccination with the mumps vaccine (containing Urabe strain) has been studied in developing countries. A lower antigen response was found in subjects with measles and mumps vaccination for a nine-month-old group than for a 12&#x02013;15-month-old group in India [<xref rid="B110-ijerph-17-01686" ref-type="bibr">110</xref>]. Among children aged 12 months, the immunogenicity response rate was 98% in Taiwan [<xref rid="B111-ijerph-17-01686" ref-type="bibr">111</xref>] and 92% in India [<xref rid="B110-ijerph-17-01686" ref-type="bibr">110</xref>]. In the United Kingdom, a study showed that the seropositivity rates were 85% at 4 years after a single dose of MMR vaccination with the Urabe strain vaccine, compared with 81% for vaccination with the Jeryl Lynn strain [<xref rid="B112-ijerph-17-01686" ref-type="bibr">112</xref>]. In Canada, a study found that five to six years after one dose of MMR vaccine, the seropositivity rate was 93% for the Urabe strain, compared with 85% for the Jeryl Lynn strain [<xref rid="B113-ijerph-17-01686" ref-type="bibr">113</xref>,<xref rid="B114-ijerph-17-01686" ref-type="bibr">114</xref>,<xref rid="B115-ijerph-17-01686" ref-type="bibr">115</xref>].</p><p>In 1997, a study on children aged 1&#x02013;11 years vaccinated with MMR (containing the Urabe strain) vaccine was conducted in northeastern Brazil [<xref rid="B116-ijerph-17-01686" ref-type="bibr">116</xref>]. This study showed a higher occurrence of aseptic meningitis 3 weeks after Brazil&#x02019;s national vaccination day (relative risk = 14.3; 95% confidence interval: 7.9, 25.7), compared with the risk in the pre-vaccination period. This result was confirmed by a case series analysis (relative risk = 30.4; 95% confidence interval: 11.5, 80.8). The estimated risk of aseptic meningitis among children who received MMR (containing Urabe strain) vaccination was 1 in 14,000 doses [<xref rid="B116-ijerph-17-01686" ref-type="bibr">116</xref>].</p><p>Canada developed molecular studies on mumps vaccine when the authorities received the reports of aseptic meningitis cases related to the vaccination with MMR vaccine (containing the Urabe mumps virus strain) [<xref rid="B117-ijerph-17-01686" ref-type="bibr">117</xref>]. It was found that the Urabe vaccine was a mixture wild type A and variant G virus strains [<xref rid="B116-ijerph-17-01686" ref-type="bibr">116</xref>]. The MMR vaccine (containing the Urabe strain) was therefore withdrawn from the market in Canada in 1990 [<xref rid="B118-ijerph-17-01686" ref-type="bibr">118</xref>]. The reason for the high rate of vaccine-associated disease with the Urabe AM9 vaccine is not clear [<xref rid="B114-ijerph-17-01686" ref-type="bibr">114</xref>]. A study in United Kingdom showed that the rate of aseptic meningitis was 9 cases per 100,000 vaccine doses [<xref rid="B119-ijerph-17-01686" ref-type="bibr">119</xref>]. This result was confirmed by a study conducted in multicenter. According to these findings, mumps vaccine (containing Urabe strain) was stopped purchasing in the United Kingdom in 1992. In Japan, nationwide surveillance was run by the Japan Ministry of Health and Welfare during 1989, and reported an incidence of 49 cases of aseptic meningitis per 100,000 doses of MMR vaccine (containing the Urabe mumps strain) [<xref rid="B120-ijerph-17-01686" ref-type="bibr">120</xref>]. Until 1993, a cumulative incidence of aseptic meningitis achieved 100 cases per 100,000 doses of MMR (containing the Urabe mumps strain), therefore all MMR vaccines were withdrawn from market of Japan in April 1993 [<xref rid="B121-ijerph-17-01686" ref-type="bibr">121</xref>].</p></sec></sec><sec id="sec5-ijerph-17-01686"><title>5. Emerging Mumps Virus Infection</title><p>Whereas most (&#x0003e;90%) of children experienced mumps infection by age 20 in pre-vaccine era, number of mumps cases declined sharply after introduction of mumps vaccine globally (<xref rid="ijerph-17-01686-t001" ref-type="table">Table 1</xref>). Incidence of MuV infection among vaccinated school- and high school-age children increased in the late 1980s, followed by sustained decrease in incidence after children were recommended to receive a second dose of MMR vaccine at four six years of age [<xref rid="B41-ijerph-17-01686" ref-type="bibr">41</xref>]. However, resurgence of outbreaks of MuV infection continues to occur in developed countries in recent years [<xref rid="B7-ijerph-17-01686" ref-type="bibr">7</xref>,<xref rid="B18-ijerph-17-01686" ref-type="bibr">18</xref>,<xref rid="B29-ijerph-17-01686" ref-type="bibr">29</xref>]. Based on the previous studies [<xref rid="B77-ijerph-17-01686" ref-type="bibr">77</xref>,<xref rid="B83-ijerph-17-01686" ref-type="bibr">83</xref>,<xref rid="B85-ijerph-17-01686" ref-type="bibr">85</xref>], the vaccine has proven itself to be highly efficacious. What factors contribute to the occurrence of mumps cases? There are several hypotheses to explain the increasing number of mumps outbreak: (1) antigenic differences between 1967 vaccine strain and contemporary circulating strains might permit immune escape. However, this theory seems unlikely given that sera collected from individuals shortly after vaccination have been shown to effectively neutralize a mass array of genetically disparate virus strains [<xref rid="B122-ijerph-17-01686" ref-type="bibr">122</xref>]; (2) waning of vaccine-induced immunity have been proposed as a likely contributor of mumps outbreaks [<xref rid="B88-ijerph-17-01686" ref-type="bibr">88</xref>]. Several studies have shown time after vaccination with declining concentrations of mumps virus-specific antibodies, decreased vaccine effectiveness, and increased risk of suffering from mumps virus infection [<xref rid="B7-ijerph-17-01686" ref-type="bibr">7</xref>,<xref rid="B123-ijerph-17-01686" ref-type="bibr">123</xref>].</p><p>The hypothesis that waning immunity is a cause of global resurgence in mumps cases suggests administration of an additional dose of vaccine during adolescence [<xref rid="B77-ijerph-17-01686" ref-type="bibr">77</xref>,<xref rid="B124-ijerph-17-01686" ref-type="bibr">124</xref>]. Between 2016 and 2017, there are numerous mumps outbreaks occurred throughout United States. To reflex these urgent events, the Advisory Committee on Immunization Practices (ACIP) recommended a third dose of MMR vaccine for groups of persons justified by public health authorities at increased risk for acquiring mumps due to an outbreak of mumps [<xref rid="B5-ijerph-17-01686" ref-type="bibr">5</xref>]. Subsequently, a guidance was developed by the Centers for Disease Control (CDC) and Prevention in the US to assist public health authorities when making decisions that effect groups at risk of acquiring mumps. Such groups should receive a third dose of the mumps vaccine. Based on the CDC guidance, public health authorities may opt to use when considering a third dose of MMR for controlling mumps outbreak [<xref rid="B5-ijerph-17-01686" ref-type="bibr">5</xref>].</p></sec><sec sec-type="conclusions" id="sec6-ijerph-17-01686"><title>6. Conclusions</title><p>In summary, although mumps is a benign clinical disease, it has become an important re-emerging pathogen. The reemergence of MuV infection will continue to threaten people unless additional preventive measures are implemented. Mumps vaccine strains have been used in the world and have shown that live mumps vaccines are highly cost-effectiveness for vaccination, despite the occasional occurrence of aseptic meningitis. Improving our understanding of mumps virus infection epidemiology, pathogenesis, and concerns over vaccine safety and efficacy are important steps to better intervene in the mumps virus infection spread.</p></sec></body><back><notes><title>Author Contributions</title><p>Conceptualization: S.-B.S. and K.-T.C.; Methodology: S.-B.S., H.-L.C., and K.-T.C.; Data curation: S.-B.S. and H.-L.C.; Draft preparation: S.-B.S. and K.-T.C.; Review and editing: K.-T.C.; All authors approved the final version of the manuscript.</p></notes><notes><title>Funding</title><p>This study was supported by a grant (RD-108007) from Tainan Municipal Hospital (managed by Show Chwan Medical Care Corporation), Tainan, Taiwan.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest exist.</p></notes><ref-list><title>References</title><ref id="B1-ijerph-17-01686"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hviid</surname><given-names>A.</given-names></name><name><surname>Rubin</surname><given-names>S.</given-names></name><name><surname>Muhlemann</surname><given-names>K.</given-names></name></person-group><article-title>Mumps</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>932</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60419-5</pub-id><pub-id pub-id-type="pmid">18342688</pub-id></element-citation></ref><ref id="B2-ijerph-17-01686"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bet&#x000e1;kov&#x000e1;</surname><given-names>T.</given-names></name><name><surname>Svetl&#x000ed;kov&#x000e1;</surname><given-names>D.</given-names></name><name><surname>Gocn&#x000ed;k</surname><given-names>M.</given-names></name></person-group><article-title>Overview of measles and mumps vaccine: Origin, present, and future of vaccine production</article-title><source>Acta Virol.</source><year>2013</year><volume>57</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.4149/av_2013_02_91</pub-id><?supplied-pmid 23600866?><pub-id pub-id-type="pmid">23600866</pub-id></element-citation></ref><ref id="B3-ijerph-17-01686"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>S.</given-names></name><name><surname>Kennedy</surname><given-names>R.</given-names></name><name><surname>Poland</surname><given-names>G.</given-names></name></person-group><article-title>Emerging mumps infection</article-title><source>Pediatr. Infect. Dis. J.</source><year>2016</year><volume>35</volume><fpage>799</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000001182</pub-id><pub-id pub-id-type="pmid">27097351</pub-id></element-citation></ref><ref id="B4-ijerph-17-01686"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wellington</surname><given-names>K.</given-names></name><name><surname>Goa</surname><given-names>K.L.</given-names></name></person-group><article-title>Measles, mumps, rubella vaccine (Priorix; GSK-MMR): A review of its use in the prevention of measles, mumps and rubella</article-title><source>Drugs</source><year>2003</year><volume>63</volume><fpage>2107</fpage><lpage>2126</lpage><pub-id pub-id-type="doi">10.2165/00003495-200363190-00012</pub-id><?supplied-pmid 12962524?><pub-id pub-id-type="pmid">12962524</pub-id></element-citation></ref><ref id="B5-ijerph-17-01686"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marlow</surname><given-names>M.A.</given-names></name><name><surname>Marin</surname><given-names>M.</given-names></name><name><surname>Moore</surname><given-names>K.</given-names></name><name><surname>Patel</surname><given-names>M.</given-names></name></person-group><article-title>CDC guidance for use of a third dose of MMR vaccine during outbreaks</article-title><source>J. Public Health Manag. Pract.</source><year>2020</year><volume>26</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1097/PHH.0000000000000962</pub-id><pub-id pub-id-type="pmid">30789597</pub-id></element-citation></ref><ref id="B6-ijerph-17-01686"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Loon</surname><given-names>F.P.</given-names></name><name><surname>Holmes</surname><given-names>S.J.</given-names></name><name><surname>Sirotkin</surname><given-names>B.I.</given-names></name><name><surname>Williams</surname><given-names>W.W.</given-names></name><name><surname>Cochi</surname><given-names>S.L.</given-names></name><name><surname>Hadler</surname><given-names>S.C.</given-names></name><name><surname>Lindegren</surname><given-names>M.L.</given-names></name></person-group><article-title>Mumps surveillance&#x02014;United States, 1988&#x02013;1993</article-title><source>MMWR CDC Surveill. Summ.</source><year>1995</year><volume>44</volume><fpage>1</fpage><lpage>14</lpage></element-citation></ref><ref id="B7-ijerph-17-01686"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewnard</surname><given-names>J.A.</given-names></name><name><surname>Grad</surname><given-names>Y.H.</given-names></name></person-group><article-title>Vaccine waning and mumps re-emergence in the United States</article-title><source>Sci. Transl. Med.</source><year>2018</year><pub-id pub-id-type="doi">10.1126/scitranslmed.aao5945</pub-id></element-citation></ref><ref id="B8-ijerph-17-01686"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagenvoort</surname><given-names>J.H.</given-names></name><name><surname>Harmsen</surname><given-names>M.</given-names></name><name><surname>Boutahar-Trouw</surname><given-names>B.J.</given-names></name><name><surname>Kraaijeveld</surname><given-names>C.A.</given-names></name><name><surname>Winkler</surname><given-names>K.C.</given-names></name></person-group><article-title>Epidemiology of mumps in The Netherlands</article-title><source>J. Hyg.</source><year>1980</year><volume>85</volume><fpage>313</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1017/S0022172400063385</pub-id><pub-id pub-id-type="pmid">7462586</pub-id></element-citation></ref><ref id="B9-ijerph-17-01686"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>R.M.</given-names></name><name><surname>Crombie</surname><given-names>J.A.</given-names></name><name><surname>Grenfell</surname><given-names>B.T.</given-names></name></person-group><article-title>The epidemiology of mumps in the UK: A preliminary study of virus transmission, herd immunity and the potential impact of immunization</article-title><source>Epidemiol. Infect.</source><year>1987</year><volume>99</volume><fpage>65</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1017/S0950268800066875</pub-id><pub-id pub-id-type="pmid">3609175</pub-id></element-citation></ref><ref id="B10-ijerph-17-01686"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gay</surname><given-names>N.</given-names></name><name><surname>Miller</surname><given-names>E.</given-names></name><name><surname>Hesketh</surname><given-names>L.</given-names></name><name><surname>Morgan-Capner</surname><given-names>P.</given-names></name><name><surname>Ramsay</surname><given-names>M.</given-names></name><name><surname>Cohen</surname><given-names>B.</given-names></name><name><surname>Brown</surname><given-names>D.</given-names></name></person-group><article-title>Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule</article-title><source>Commun. Dis. Rep. CDR Rev.</source><year>1997</year><volume>7</volume><fpage>R21</fpage><lpage>R26</lpage><pub-id pub-id-type="pmid">9046125</pub-id></element-citation></ref><ref id="B11-ijerph-17-01686"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peltola</surname><given-names>H.</given-names></name><name><surname>Heinonen</surname><given-names>O.P.</given-names></name><name><surname>Valle</surname><given-names>M.</given-names></name><name><surname>Paunio</surname><given-names>M.</given-names></name><name><surname>Virtanen</surname><given-names>M.</given-names></name><name><surname>Karanko</surname><given-names>V.</given-names></name><name><surname>Cantell</surname><given-names>K.</given-names></name></person-group><article-title>The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program</article-title><source>N. Engl. J. Med.</source><year>1994</year><volume>331</volume><fpage>1397</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1056/NEJM199411243312101</pub-id><?supplied-pmid 7969278?><pub-id pub-id-type="pmid">7969278</pub-id></element-citation></ref><ref id="B12-ijerph-17-01686"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peltola</surname><given-names>H.</given-names></name><name><surname>Davidkin</surname><given-names>I.</given-names></name><name><surname>Paunio</surname><given-names>M.</given-names></name><name><surname>Valle</surname><given-names>M.</given-names></name><name><surname>Leinikki</surname><given-names>P.</given-names></name><name><surname>Heinonen</surname><given-names>O.P.</given-names></name></person-group><article-title>Mumps and rubella eliminated from Finland</article-title><source>JAMA</source><year>2000</year><volume>284</volume><fpage>2643</fpage><lpage>2647</lpage><pub-id pub-id-type="doi">10.1001/jama.284.20.2643</pub-id><?supplied-pmid 11086376?><pub-id pub-id-type="pmid">11086376</pub-id></element-citation></ref><ref id="B13-ijerph-17-01686"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falk</surname><given-names>W.A.</given-names></name><name><surname>Buchan</surname><given-names>K.</given-names></name><name><surname>Dow</surname><given-names>M.</given-names></name><name><surname>Garson</surname><given-names>J.Z.</given-names></name><name><surname>Hill</surname><given-names>E.</given-names></name><name><surname>Nosal</surname><given-names>M.</given-names></name><name><surname>Tarrant</surname><given-names>M.</given-names></name><name><surname>Westbury</surname><given-names>R.C.</given-names></name><name><surname>White</surname><given-names>F.M.</given-names></name></person-group><article-title>The epidemiology of mumps in southern Alberta, 1980&#x02013;1982</article-title><source>Am. J. Epidemiol.</source><year>1989</year><volume>130</volume><fpage>736</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a115395</pub-id><?supplied-pmid 2505612?><pub-id pub-id-type="pmid">2505612</pub-id></element-citation></ref><ref id="B14-ijerph-17-01686"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffini&#x000e8;res</surname><given-names>E.</given-names></name><name><surname>Turbelin</surname><given-names>C.</given-names></name><name><surname>Riblier</surname><given-names>D.</given-names></name><name><surname>Aouba</surname><given-names>A.</given-names></name><name><surname>Levy-Bruhl</surname><given-names>D.</given-names></name><name><surname>Arena</surname><given-names>C.</given-names></name><name><surname>Chiappe</surname><given-names>S.G.</given-names></name><name><surname>Ferry</surname><given-names>J.P.</given-names></name><name><surname>Hanslik</surname><given-names>T.</given-names></name><name><surname>Blanchon</surname><given-names>T.</given-names></name></person-group><article-title>Mumps: Burden of disease in France</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>7013</fpage><lpage>7018</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.070</pub-id><?supplied-pmid 23059354?><pub-id pub-id-type="pmid">23059354</pub-id></element-citation></ref><ref id="B15-ijerph-17-01686"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slater</surname><given-names>P.E.</given-names></name><name><surname>Roitman</surname><given-names>M.</given-names></name><name><surname>Costin</surname><given-names>C.</given-names></name></person-group><article-title>Mumps incidence in Israel&#x02014;Impact of MMR vaccine</article-title><source>Public Health Rev.</source><year>1990</year><volume>18</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">2132885</pub-id></element-citation></ref><ref id="B16-ijerph-17-01686"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngaovithunvong</surname><given-names>V.</given-names></name><name><surname>Wanlapakorn</surname><given-names>N.</given-names></name><name><surname>Tesapirat</surname><given-names>L.</given-names></name><name><surname>Suratannon</surname><given-names>N.</given-names></name><name><surname>Poovorawan</surname><given-names>Y.</given-names></name></person-group><article-title>Mumps antibody in the Thai population 17 years after the universal measles mumps rubella vaccination program</article-title><source>J. Infect. Dev. Ctries.</source><year>2016</year><volume>10</volume><fpage>735</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.3855/jidc.7560</pub-id><pub-id pub-id-type="pmid">27482805</pub-id></element-citation></ref><ref id="B17-ijerph-17-01686"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>A.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Mao</surname><given-names>N.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Mumps Epidemiology and Mumps Virus Genotypes Circulating in Mainland China during 2013&#x02013;2015</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0169561</pub-id></element-citation></ref><ref id="B18-ijerph-17-01686"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S.H.</given-names></name></person-group><article-title>Resurgence of mumps in Korea</article-title><source>Infect. Chemother.</source><year>2015</year><volume>47</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.3947/ic.2015.47.1.1</pub-id><pub-id pub-id-type="pmid">25844258</pub-id></element-citation></ref><ref id="B19-ijerph-17-01686"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aratchige</surname><given-names>P.E.</given-names></name><name><surname>McIntyre</surname><given-names>P.B.</given-names></name><name><surname>Quinn</surname><given-names>H.E.</given-names></name><name><surname>Gilbert</surname><given-names>G.L.</given-names></name></person-group><article-title>Recent increases in mumps incidence in Australia: The &#x0201c;forgotten&#x0201d; age group in the 1998 Australian Measles Control Campaign</article-title><source>Med. J. Aust.</source><year>2008</year><volume>189</volume><fpage>434</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.2008.tb02115.x</pub-id><pub-id pub-id-type="pmid">18928435</pub-id></element-citation></ref><ref id="B20-ijerph-17-01686"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.C.</given-names></name><name><surname>Lu</surname><given-names>C.C.</given-names></name><name><surname>Su</surname><given-names>B.H.</given-names></name><name><surname>Chen</surname><given-names>K.T.</given-names></name></person-group><article-title>Epidemiologic features of mumps in Taiwan from 2006 to 2011: A new challenge for public health policy</article-title><source>World J. Pediatr.</source><year>2015</year><volume>11</volume><fpage>141</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1007/s12519-014-0525-6</pub-id><pub-id pub-id-type="pmid">25416005</pub-id></element-citation></ref><ref id="B21-ijerph-17-01686"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galazka</surname><given-names>A.M.</given-names></name><name><surname>Robertson</surname><given-names>S.E.</given-names></name><name><surname>Kraigher</surname><given-names>A.</given-names></name></person-group><article-title>Mumps and mumps vaccine: A global review</article-title><source>Bull. World Health Organ.</source><year>1999</year><volume>77</volume><fpage>3</fpage><lpage>14</lpage><?supplied-pmid 10063655?><pub-id pub-id-type="pmid">10063655</pub-id></element-citation></ref><ref id="B22-ijerph-17-01686"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osborne</surname><given-names>K.</given-names></name><name><surname>Gay</surname><given-names>N.</given-names></name><name><surname>Hesketh</surname><given-names>L.</given-names></name><name><surname>Morgan-Capner</surname><given-names>P.</given-names></name><name><surname>Miller</surname><given-names>E.</given-names></name></person-group><article-title>Ten years of serological surveillance in England and Wales: Methods, results, implications and action</article-title><source>Int. J. Epidemiol.</source><year>2000</year><volume>29</volume><fpage>362</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1093/ije/29.2.362</pub-id><?supplied-pmid 10817137?><pub-id pub-id-type="pmid">10817137</pub-id></element-citation></ref><ref id="B23-ijerph-17-01686"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edmunds</surname><given-names>W.J.</given-names></name><name><surname>Gay</surname><given-names>N.J.</given-names></name><name><surname>Kretzschmar</surname><given-names>M.</given-names></name><name><surname>Pebody</surname><given-names>R.G.</given-names></name><name><surname>Wachmann</surname><given-names>H.</given-names></name><collab>ESEN Project</collab></person-group><article-title>European Sero-epidemiology Network. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: Implications for modelling studies</article-title><source>Epidemiol. Infect.</source><year>2000</year><volume>125</volume><fpage>635</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1017/S0950268800004672</pub-id><?supplied-pmid 11218214?><pub-id pub-id-type="pmid">11218214</pub-id></element-citation></ref><ref id="B24-ijerph-17-01686"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marlow</surname><given-names>R.</given-names></name><name><surname>Kuriyakose</surname><given-names>S.</given-names></name><name><surname>Mesaros</surname><given-names>N.</given-names></name><name><surname>Han</surname><given-names>H.H.</given-names></name><name><surname>Tomlinson</surname><given-names>R.</given-names></name><name><surname>Faust</surname><given-names>S.N.</given-names></name><name><surname>Snape</surname><given-names>M.</given-names></name><name><surname>Pollard</surname><given-names>A.J.</given-names></name><name><surname>Finn</surname><given-names>A.</given-names></name></person-group><article-title>A Phase III, open-label, randomized multicenter study to evaluate the immunogeneicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4 year-old healthy children in the UK</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>2300</fpage><lpage>2306</lpage><pub-id pub-id-type="pmid">29576304</pub-id></element-citation></ref><ref id="B25-ijerph-17-01686"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>A.P.</given-names></name><name><surname>Smolensky</surname><given-names>M.H.</given-names></name><name><surname>Burau</surname><given-names>K.D.</given-names></name><name><surname>Cech</surname><given-names>I.M.</given-names></name><name><surname>Lai</surname><given-names>D.</given-names></name></person-group><article-title>Seasonality of primarily childhood and young adult infectious diseases in the United States</article-title><source>Chronobiol. Int.</source><year>2006</year><volume>23</volume><fpage>1065</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1080/07420520600920718</pub-id><pub-id pub-id-type="pmid">17050218</pub-id></element-citation></ref><ref id="B26-ijerph-17-01686"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altizer</surname><given-names>S.</given-names></name><name><surname>Dobson</surname><given-names>A.</given-names></name><name><surname>Hosseini</surname><given-names>P.</given-names></name><name><surname>Hudson</surname><given-names>P.</given-names></name><name><surname>Pascual</surname><given-names>M.</given-names></name><name><surname>Rohani</surname><given-names>P.</given-names></name></person-group><article-title>Seasonality and the dynamics of infectious diseases</article-title><source>Ecol. Lett.</source><year>2006</year><volume>9</volume><fpage>467</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1111/j.1461-0248.2005.00879.x</pub-id><pub-id pub-id-type="pmid">16623732</pub-id></element-citation></ref><ref id="B27-ijerph-17-01686"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levitt</surname><given-names>L.P.</given-names></name><name><surname>Mahoney</surname><given-names>D.H.</given-names><suffix>Jr.</suffix></name><name><surname>Casey</surname><given-names>H.L.</given-names></name><name><surname>Bond</surname><given-names>J.O.</given-names></name></person-group><article-title>Mumps in a general population. A sero-epidemiologic study</article-title><source>Am. J. Dis. Child.</source><year>1970</year><volume>120</volume><fpage>134</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1001/archpedi.1970.02100070078008</pub-id><pub-id pub-id-type="pmid">5454932</pub-id></element-citation></ref><ref id="B28-ijerph-17-01686"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksen</surname><given-names>J.</given-names></name><name><surname>Davidkin</surname><given-names>I.</given-names></name><name><surname>Kafatos</surname><given-names>G.</given-names></name><name><surname>Andrews</surname><given-names>N.</given-names></name><name><surname>Barbara</surname><given-names>C.</given-names></name><name><surname>Cohen</surname><given-names>D.</given-names></name><name><surname>Duks</surname><given-names>A.</given-names></name><name><surname>Griskevicius</surname><given-names>A.</given-names></name><name><surname>Johansen</surname><given-names>K.</given-names></name><name><surname>Bartha</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Seroepidemiology of mumps in Europe (1996&#x02013;2008): Why do outbreaks occur in highly vaccinated populations?</article-title><source>Epidemiol. Infect.</source><year>2013</year><volume>141</volume><fpage>651</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1017/S0950268812001136</pub-id><pub-id pub-id-type="pmid">22687578</pub-id></element-citation></ref><ref id="B29-ijerph-17-01686"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e9;raud</surname><given-names>G.</given-names></name><name><surname>Abrams</surname><given-names>S.</given-names></name><name><surname>Beutels</surname><given-names>P.</given-names></name><name><surname>Dervaux</surname><given-names>B.</given-names></name><name><surname>Hens</surname><given-names>N.</given-names></name></person-group><article-title>Resurgence risk for measles, mumps and rubella in France in 2018 and 2020</article-title><source>Eurosurveillance</source><year>2018</year><volume>23</volume><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2018.23.25.1700796</pub-id></element-citation></ref><ref id="B30-ijerph-17-01686"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metcalf</surname><given-names>C.J.E.</given-names></name><name><surname>Graham</surname><given-names>A.L.</given-names></name><name><surname>Grenfell</surname><given-names>B.T.</given-names></name></person-group><article-title>Understanding Herd Immunity</article-title><source>Trends Immunol.</source><year>2015</year><volume>36</volume><fpage>753</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1016/j.it.2015.10.004</pub-id><pub-id pub-id-type="pmid">26683689</pub-id></element-citation></ref><ref id="B31-ijerph-17-01686"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeBaron</surname><given-names>C.W.</given-names></name><name><surname>Forghani</surname><given-names>B.</given-names></name><name><surname>Matter</surname><given-names>L.</given-names></name><name><surname>Reef</surname><given-names>S.E.</given-names></name><name><surname>Beck</surname><given-names>C.</given-names></name><name><surname>Bi</surname><given-names>D.</given-names></name><name><surname>Cossen</surname><given-names>C.</given-names></name><name><surname>Sullivan</surname><given-names>B.J.</given-names></name></person-group><article-title>Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine</article-title><source>J. Infect. Dis.</source><year>2009</year><volume>200</volume><fpage>888</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1086/605410</pub-id><?supplied-pmid 19659440?><pub-id pub-id-type="pmid">19659440</pub-id></element-citation></ref><ref id="B32-ijerph-17-01686"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidkin</surname><given-names>I.</given-names></name><name><surname>Jokinen</surname><given-names>S.</given-names></name><name><surname>Broman</surname><given-names>M.</given-names></name><name><surname>Leinikki</surname><given-names>P.</given-names></name><name><surname>Peltola</surname><given-names>H.</given-names></name></person-group><article-title>Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: A 20-year follow-up</article-title><source>J. Infect. Dis.</source><year>2008</year><volume>197</volume><fpage>950</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1086/528993</pub-id><pub-id pub-id-type="pmid">18419470</pub-id></element-citation></ref><ref id="B33-ijerph-17-01686"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauldin</surname><given-names>J.</given-names></name><name><surname>Carbone</surname><given-names>K.</given-names></name><name><surname>Hsu</surname><given-names>H.</given-names></name><name><surname>Yolken</surname><given-names>R.</given-names></name><name><surname>Rubin</surname><given-names>S.</given-names></name></person-group><article-title>Mumps virus-specific antibody titers from pre-vaccine era sera: Comparison of the plaque reduction neutralization assay and enzyme immunoassays</article-title><source>J. Clin. Microbiol.</source><year>2005</year><volume>43</volume><fpage>4847</fpage><lpage>4851</lpage><pub-id pub-id-type="doi">10.1128/JCM.43.9.4847-4851.2005</pub-id><?supplied-pmid 16145156?><pub-id pub-id-type="pmid">16145156</pub-id></element-citation></ref><ref id="B34-ijerph-17-01686"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vyse</surname><given-names>A.J.</given-names></name><name><surname>Gay</surname><given-names>N.J.</given-names></name><name><surname>Hesketh</surname><given-names>L.M.</given-names></name><name><surname>Pebody</surname><given-names>R.</given-names></name><name><surname>Morgan-Capner</surname><given-names>P.</given-names></name><name><surname>Miller</surname><given-names>E.</given-names></name></person-group><article-title>Interpreting serological surveys using mixture models: The seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century</article-title><source>Epidemiol. Infect.</source><year>2006</year><volume>134</volume><fpage>1303</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1017/S0950268806006340</pub-id><?supplied-pmid 16650326?><pub-id pub-id-type="pmid">16650326</pub-id></element-citation></ref><ref id="B35-ijerph-17-01686"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>Y.C.</given-names></name><name><surname>Su</surname><given-names>B.H.</given-names></name><name><surname>Su</surname><given-names>H.J.</given-names></name><name><surname>Chang</surname><given-names>H.L.</given-names></name><name><surname>Lin</surname><given-names>C.Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>K.T.</given-names></name></person-group><article-title>The association between the incidence of mumps and meteorological parameters in Taiwan. Hum</article-title><source>Vaccin. Immunother.</source><year>2015</year><volume>11</volume><fpage>1406</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1029687</pub-id><?supplied-pmid 25891825?><pub-id pub-id-type="pmid">25891825</pub-id></element-citation></ref><ref id="B36-ijerph-17-01686"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Ding</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Dong</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>G.</given-names></name><name><surname>Fu</surname><given-names>C.</given-names></name></person-group><article-title>The relationship between meteorological factors and mumps incidence in Guangzhou, China, 2005&#x02013;2012</article-title><source>Hum. Vaccin. Immunother.</source><year>2014</year><volume>10</volume><fpage>2421</fpage><lpage>2432</lpage><pub-id pub-id-type="doi">10.4161/hv.29286</pub-id><?supplied-pmid 25424950?><pub-id pub-id-type="pmid">25424950</pub-id></element-citation></ref><ref id="B37-ijerph-17-01686"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onozuka</surname><given-names>D.</given-names></name><name><surname>Hashizume</surname><given-names>M.</given-names></name></person-group><article-title>Effect of weather variability on the incidence of mumps in children: A time-series analysis</article-title><source>Epidemiol. Infect.</source><year>2011</year><volume>139</volume><fpage>1692</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1017/S0950268810002967</pub-id><pub-id pub-id-type="pmid">21211102</pub-id></element-citation></ref><ref id="B38-ijerph-17-01686"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisman</surname><given-names>D.N.</given-names></name></person-group><article-title>Seasonality of infectious diseases</article-title><source>Annu. Rev. Public Health</source><year>2007</year><volume>28</volume><fpage>127</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1146/annurev.publhealth.28.021406.144128</pub-id><pub-id pub-id-type="pmid">17222079</pub-id></element-citation></ref><ref id="B39-ijerph-17-01686"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Ou</surname><given-names>R.</given-names></name><name><surname>Xiang</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Jing</surname><given-names>D.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Ye</surname><given-names>M.</given-names></name></person-group><article-title>Epidemiological Characteristics and Spatiotemporal Analysis of Mumps from 2004 to 2018 in Chongqing, China</article-title><source>Int. J. Environ. Res. Public Health</source><year>2019</year><volume>16</volume><elocation-id>3052</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph16173052</pub-id></element-citation></ref><ref id="B40-ijerph-17-01686"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>S.</given-names></name><name><surname>Eckhaus</surname><given-names>M.</given-names></name><name><surname>Rennick</surname><given-names>L.J.</given-names></name><name><surname>Bamford</surname><given-names>C.G.</given-names></name><name><surname>Duprex</surname><given-names>W.P.</given-names></name></person-group><article-title>Molecular biology, pathogenesis and pathology of mumps virus</article-title><source>J. Pathol.</source><year>2015</year><volume>235</volume><fpage>242</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1002/path.4445</pub-id><pub-id pub-id-type="pmid">25229387</pub-id></element-citation></ref><ref id="B41-ijerph-17-01686"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control (CDC)</collab></person-group><article-title>Mumps prevention</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>1989</year><volume>38</volume><fpage>388</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">2498629</pub-id></element-citation></ref><ref id="B42-ijerph-17-01686"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peltola</surname><given-names>H.</given-names></name><name><surname>Kulkarni</surname><given-names>P.S.</given-names></name><name><surname>Kapre</surname><given-names>S.V.</given-names></name><name><surname>Paunio</surname><given-names>M.</given-names></name><name><surname>Jadhav</surname><given-names>S.S.</given-names></name><name><surname>Dhere</surname><given-names>R.M.</given-names></name></person-group><article-title>Mumps outbreaks in Canada and the United States: Time for new thinking on mumps vaccines</article-title><source>Clin. Infect. Dis.</source><year>2007</year><volume>45</volume><fpage>459</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1086/520028</pub-id><pub-id pub-id-type="pmid">17638194</pub-id></element-citation></ref><ref id="B43-ijerph-17-01686"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandermeulen</surname><given-names>C.</given-names></name><name><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name><surname>Hoppenbrouwers</surname><given-names>K.</given-names></name></person-group><article-title>Mumps outbreaks in highly vaccinated populations: What makes good even better?</article-title><source>Hum. Vaccin.</source><year>2009</year><volume>5</volume><fpage>494</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.4161/hv.7943</pub-id><?supplied-pmid 19279405?><pub-id pub-id-type="pmid">19279405</pub-id></element-citation></ref><ref id="B44-ijerph-17-01686"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boxall</surname><given-names>N.</given-names></name><name><surname>Kubinyiova</surname><given-names>M.</given-names></name><name><surname>Pr&#x000ed;kazsk&#x000fd;</surname><given-names>V.</given-names></name><name><surname>Benes</surname><given-names>C.</given-names></name><name><surname>C&#x000e1;stkov&#x000e1;</surname><given-names>J.</given-names></name></person-group><article-title>An increase in the number of mumps cases in the Czech Republic, 2005&#x02013;2006</article-title><source>Eurosurveillance</source><year>2008</year><volume>13</volume><fpage>146</fpage><lpage>149</lpage></element-citation></ref><ref id="B45-ijerph-17-01686"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>D.W.</given-names></name><name><surname>Nam</surname><given-names>M.H.</given-names></name><name><surname>Kim</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Sohn</surname><given-names>J.W.</given-names></name><name><surname>Cho</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>K.J.</given-names></name><name><surname>Kim</surname><given-names>M.J.</given-names></name></person-group><article-title>Mumps outbreak in highly vaccinated school population: Assessment of secondary vaccine failure using IgG avidity measurements</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>4665</fpage><lpage>4670</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.04.013</pub-id><pub-id pub-id-type="pmid">17498856</pub-id></element-citation></ref><ref id="B46-ijerph-17-01686"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fields</surname><given-names>V.S.</given-names></name><name><surname>Safi</surname><given-names>H.</given-names></name><name><surname>Waters</surname><given-names>C.</given-names></name><name><surname>Dillaha</surname><given-names>J.</given-names></name><name><surname>Capelle</surname><given-names>L.</given-names></name><name><surname>Riklon</surname><given-names>S.</given-names></name><name><surname>Wheeler</surname><given-names>J.G.</given-names></name><name><surname>Haselow</surname><given-names>D.T.</given-names></name></person-group><article-title>Mumps in a highly vaccinated Marshallese community in Arkansas, USA: An outbreak report</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30607-8</pub-id><pub-id pub-id-type="pmid">30635255</pub-id></element-citation></ref><ref id="B47-ijerph-17-01686"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vygen</surname><given-names>S.</given-names></name><name><surname>Fischer</surname><given-names>A.</given-names></name><name><surname>Meurice</surname><given-names>L.</given-names></name><name><surname>Mounchetrou</surname><given-names>N.I.</given-names></name><name><surname>Gregoris</surname><given-names>M.</given-names></name><name><surname>Ndiaye</surname><given-names>B.</given-names></name><name><surname>Ghenassia</surname><given-names>A.</given-names></name><name><surname>Poujol</surname><given-names>I.</given-names></name><name><surname>Stahl</surname><given-names>J.P.</given-names></name><name><surname>Antona</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Waning immunity against mumps in Vaccinated young adults, France 2013</article-title><source>Eurosurveillance</source><year>2016</year><volume>21</volume><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2016.21.10.30156</pub-id></element-citation></ref><ref id="B48-ijerph-17-01686"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aasheim</surname><given-names>E.T.</given-names></name><name><surname>Inns</surname><given-names>T.</given-names></name><name><surname>Trindall</surname><given-names>A.</given-names></name><name><surname>Emmett</surname><given-names>L.</given-names></name><name><surname>Brown</surname><given-names>K.E.</given-names></name><name><surname>Williams</surname><given-names>C.J.</given-names></name><name><surname>Reacher</surname><given-names>M.</given-names></name></person-group><article-title>Outbreak of mumps in a school setting, United Kingdom, 2013</article-title><source>Hum. Vaccin. Immunother.</source><year>2014</year><volume>10</volume><fpage>2446</fpage><lpage>2449</lpage><pub-id pub-id-type="doi">10.4161/hv.29484</pub-id><pub-id pub-id-type="pmid">25424953</pub-id></element-citation></ref><ref id="B49-ijerph-17-01686"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westphal</surname><given-names>D.W.</given-names></name><name><surname>Eastwood</surname><given-names>A.</given-names></name><name><surname>Levy</surname><given-names>A.</given-names></name><name><surname>Davies</surname><given-names>J.</given-names></name><name><surname>Huppatz</surname><given-names>C.</given-names></name><name><surname>Gilles</surname><given-names>M.</given-names></name><name><surname>Lyttle</surname><given-names>H.</given-names></name><name><surname>Williams</surname><given-names>S.A.</given-names></name><name><surname>Dowse</surname><given-names>G.K.</given-names></name></person-group><article-title>A protracted mumps outbreak in Western Australia despite high vaccine coverage: A population-based surveillance study</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30498-5</pub-id><pub-id pub-id-type="pmid">30558994</pub-id></element-citation></ref><ref id="B50-ijerph-17-01686"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayan</surname><given-names>G.H.</given-names></name><name><surname>Quinlisk</surname><given-names>M.P.</given-names></name><name><surname>Parker</surname><given-names>A.A.</given-names></name><name><surname>Barskey</surname><given-names>A.E.</given-names></name><name><surname>Harris</surname><given-names>M.L.</given-names></name><name><surname>Schwartz</surname><given-names>J.M.</given-names></name><name><surname>Hunt</surname><given-names>K.</given-names></name><name><surname>Finley</surname><given-names>C.G.</given-names></name><name><surname>Leschinsky</surname><given-names>D.P.</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>Recent resurgence of mumps in the United States</article-title><source>N. Engl. J. Med.</source><year>2008</year><volume>358</volume><fpage>1580</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0706589</pub-id><pub-id pub-id-type="pmid">18403766</pub-id></element-citation></ref><ref id="B51-ijerph-17-01686"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bag</surname><given-names>S.K.</given-names></name><name><surname>Dey</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Beard</surname><given-names>F.</given-names></name></person-group><article-title>Australian vaccine preventable disease epidemiological review series: Mumps 2008-2012</article-title><source>Commun. Dis Intell. Q. Report.</source><year>2015</year><volume>39</volume><fpage>E10</fpage><lpage>E18</lpage></element-citation></ref><ref id="B52-ijerph-17-01686"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>N.G.</given-names></name><name><surname>Bernard</surname><given-names>H.</given-names></name><name><surname>Melnic</surname><given-names>A.</given-names></name><name><surname>Bucov</surname><given-names>V.</given-names></name><name><surname>Caterinciuc</surname><given-names>N.</given-names></name><name><surname>an der Heiden</surname><given-names>M.</given-names></name><name><surname>Andrews</surname><given-names>N.</given-names></name><name><surname>Pebody</surname><given-names>R.</given-names></name><name><surname>Aidyralieva</surname><given-names>C.</given-names></name><name><surname>Hahn&#x000e9;</surname><given-names>S.</given-names></name></person-group><article-title>Mumps outbreak in the Republic of Moldova, 2007&#x02013;2008</article-title><source>Pediatr. Infect. Dis. J.</source><year>2010</year><volume>29</volume><fpage>703</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1097/INF.0b013e3181d743df</pub-id><?supplied-pmid 20308934?><pub-id pub-id-type="pmid">20308934</pub-id></element-citation></ref><ref id="B53-ijerph-17-01686"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pebody</surname><given-names>R.G.</given-names></name><name><surname>Gay</surname><given-names>N.J.</given-names></name><name><surname>Hesketh</surname><given-names>L.M.</given-names></name><name><surname>Vyse</surname><given-names>A.</given-names></name><name><surname>Morgan-Capner</surname><given-names>P.</given-names></name><name><surname>Brown</surname><given-names>D.W.</given-names></name><name><surname>Litton</surname><given-names>P.</given-names></name><name><surname>Miller</surname><given-names>E.</given-names></name></person-group><article-title>Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>1134</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00435-2</pub-id><pub-id pub-id-type="pmid">11803074</pub-id></element-citation></ref><ref id="B54-ijerph-17-01686"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castilla</surname><given-names>J.</given-names></name><name><surname>Garc&#x000ed;a Cenoz</surname><given-names>M.</given-names></name><name><surname>Arriazu</surname><given-names>M.</given-names></name><name><surname>Fern&#x000e1;ndez-Alonso</surname><given-names>M.</given-names></name><name><surname>Mart&#x000ed;nez-Artola</surname><given-names>V.</given-names></name><name><surname>Etxeberria</surname><given-names>J.</given-names></name><name><surname>Irisarri</surname><given-names>F.</given-names></name><name><surname>Barricarte</surname><given-names>A.</given-names></name></person-group><article-title>Effectiveness of Jeryl Lynn-containing vaccine in Spanish children</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>2089</fpage><lpage>2093</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.001</pub-id><pub-id pub-id-type="pmid">19356610</pub-id></element-citation></ref><ref id="B55-ijerph-17-01686"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>C.</given-names></name><name><surname>White</surname><given-names>J.M.</given-names></name><name><surname>Savage</surname><given-names>E.J.</given-names></name><name><surname>Glynn</surname><given-names>J.R.</given-names></name><name><surname>Choi</surname><given-names>Y.</given-names></name><name><surname>Andrews</surname><given-names>N.</given-names></name><name><surname>Brown</surname><given-names>D.</given-names></name><name><surname>Ramsay</surname><given-names>M.E.</given-names></name></person-group><article-title>Vaccine effectiveness estimates, 2004&#x02013;2005 mumps outbreak, England</article-title><source>Emerg. Infect. Dis.</source><year>2007</year><volume>13</volume><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.3201/eid1301.060649</pub-id><pub-id pub-id-type="pmid">17370510</pub-id></element-citation></ref><ref id="B56-ijerph-17-01686"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayan</surname><given-names>G.H.</given-names></name><name><surname>Rubin</surname><given-names>S.</given-names></name></person-group><article-title>Mumps outbreaks in vaccinated populations: Are available mumps vaccines effective enough to prevent outbreaks?</article-title><source>Clin. Infect. Dis.</source><year>2008</year><volume>47</volume><fpage>1458</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1086/591196</pub-id><pub-id pub-id-type="pmid">18959494</pub-id></element-citation></ref><ref id="B57-ijerph-17-01686"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R.K.</given-names></name><name><surname>Best</surname><given-names>J.</given-names></name><name><surname>MacMahon</surname><given-names>E.</given-names></name></person-group><article-title>Mumps and the UK epidemic 2005</article-title><source>BMJ</source><year>2005</year><volume>330</volume><fpage>1132</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1136/bmj.330.7500.1132</pub-id><pub-id pub-id-type="pmid">15891229</pub-id></element-citation></ref><ref id="B58-ijerph-17-01686"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foy</surname><given-names>H.M.</given-names></name><name><surname>Cooney</surname><given-names>M.K.</given-names></name><name><surname>Hall</surname><given-names>C.E.</given-names></name><name><surname>Bor</surname><given-names>E.</given-names></name><name><surname>Maletzky</surname><given-names>A.J.</given-names></name></person-group><article-title>Isolation of mumps virus from children with acute lower respiratory tract disease</article-title><source>Am J Epidemiol.</source><year>1971</year><volume>94</volume><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a121343</pub-id><pub-id pub-id-type="pmid">5120542</pub-id></element-citation></ref><ref id="B59-ijerph-17-01686"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>&#x000d6;rvell</surname><given-names>C.</given-names></name><name><surname>Myers</surname><given-names>R.</given-names></name><name><surname>Rota</surname><given-names>P.A.</given-names></name><name><surname>Nakayama</surname><given-names>T.</given-names></name><name><surname>Forcic</surname><given-names>D.</given-names></name><name><surname>Hiebert</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>K.E.</given-names></name></person-group><article-title>Genomic diversity of mumps virus and global distribution of the 12 genotypes</article-title><source>Rev. Med. Virol.</source><year>2015</year><volume>25</volume><fpage>85</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1002/rmv.1819</pub-id><pub-id pub-id-type="pmid">25424978</pub-id></element-citation></ref><ref id="B60-ijerph-17-01686"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>A.</given-names></name><name><surname>Yamaji</surname><given-names>Y.</given-names></name><name><surname>Nakayama</surname><given-names>T.</given-names></name></person-group><article-title>Mumps Hoshino and Torii vaccine strains were distinguished from circulating wild strains</article-title><source>J. Infect. Chemorther.</source><year>2013</year><volume>19</volume><fpage>480</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1007/s10156-012-0515-3</pub-id></element-citation></ref><ref id="B61-ijerph-17-01686"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maillet</surname><given-names>M.</given-names></name><name><surname>Bouvat</surname><given-names>E.</given-names></name><name><surname>Robert</surname><given-names>N.</given-names></name><name><surname>Baccard-Long&#x000e8;re</surname><given-names>M.</given-names></name><name><surname>Morel-Baccard</surname><given-names>C.</given-names></name><name><surname>Morand</surname><given-names>P.</given-names></name><name><surname>Vabret</surname><given-names>A.</given-names></name><name><surname>Stahl</surname><given-names>J.P.</given-names></name></person-group><article-title>Mumps outbreak and laboratory diagnosis</article-title><source>J. Clin. Virol.</source><year>2015</year><volume>62</volume><fpage>14</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2014.11.004</pub-id><?supplied-pmid 25542464?><pub-id pub-id-type="pmid">25542464</pub-id></element-citation></ref><ref id="B62-ijerph-17-01686"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ennis</surname><given-names>F.A.</given-names></name><name><surname>Jackson</surname><given-names>D.</given-names></name></person-group><article-title>Isolation of virus during the incubation period of mumps infection</article-title><source>J. Pediatr.</source><year>1968</year><volume>72</volume><fpage>536</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(68)80347-6</pub-id><pub-id pub-id-type="pmid">5647297</pub-id></element-citation></ref><ref id="B63-ijerph-17-01686"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katoh</surname><given-names>H.</given-names></name><name><surname>Nakatsu</surname><given-names>Y.</given-names></name><name><surname>Kubota</surname><given-names>T.</given-names></name><name><surname>Sakata</surname><given-names>M.</given-names></name><name><surname>Takeda</surname><given-names>M.</given-names></name><name><surname>Kidokoro</surname><given-names>M.</given-names></name></person-group><article-title>Mumps Virus Is Released from the Apical Surface of Polarized Epithelial Cells, and the Release Is Facilitated by a Rab11-Mediated Transport System</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>12026</fpage><lpage>12034</lpage><pub-id pub-id-type="doi">10.1128/JVI.02048-15</pub-id><?supplied-pmid 26378159?><pub-id pub-id-type="pmid">26378159</pub-id></element-citation></ref><ref id="B64-ijerph-17-01686"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overman</surname><given-names>J.R.</given-names></name></person-group><article-title>Viremia in human mumps virus infections</article-title><source>Arch. Intern. Med.</source><year>1958</year><volume>102</volume><fpage>354</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1001/archinte.1958.00030010354002</pub-id></element-citation></ref><ref id="B65-ijerph-17-01686"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooney</surname><given-names>M.K.</given-names></name><name><surname>Fox</surname><given-names>J.P.</given-names></name><name><surname>Hall</surname><given-names>C.E.</given-names></name></person-group><article-title>The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and <italic>Mycoplasma pneumoniae</italic></article-title><source>Am. J. Epidemiol.</source><year>1975</year><volume>101</volume><fpage>532</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a112125</pub-id><pub-id pub-id-type="pmid">168766</pub-id></element-citation></ref><ref id="B66-ijerph-17-01686"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>D.A.</given-names></name></person-group><article-title>Vaccine-Preventable Diseases In Pediatric Patients: A Review Of Measles, Mumps, Rubella, And Varicella</article-title><source>Pediatr. Emerg. Med. Pract.</source><year>2016</year><volume>13</volume><fpage>1</fpage><lpage>20</lpage></element-citation></ref><ref id="B67-ijerph-17-01686"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bockelman</surname><given-names>C.</given-names></name><name><surname>Frawley</surname><given-names>T.C.</given-names></name><name><surname>Long</surname><given-names>B.</given-names></name><name><surname>Koyfman</surname><given-names>A.</given-names></name></person-group><article-title>Mumps: An Emergency Medicine-Focused Update</article-title><source>J. Emerg. Med.</source><year>2018</year><volume>54</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.jemermed.2017.08.037</pub-id><pub-id pub-id-type="pmid">29110978</pub-id></element-citation></ref><ref id="B68-ijerph-17-01686"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabaku&#x0015f;</surname><given-names>N.</given-names></name><name><surname>Aydino&#x0011f;lu</surname><given-names>H.</given-names></name><name><surname>Yekeler</surname><given-names>H.</given-names></name><name><surname>Arslan</surname><given-names>I.N.</given-names></name></person-group><article-title>Fatal mumps nephritis and myocarditis</article-title><source>J. Trop. Pediatr.</source><year>1999</year><volume>45</volume><fpage>358</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1093/tropej/45.6.358</pub-id><pub-id pub-id-type="pmid">10667005</pub-id></element-citation></ref><ref id="B69-ijerph-17-01686"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ternavasio-de la Vega</surname><given-names>H.G.</given-names></name><name><surname>Boronat</surname><given-names>M.</given-names></name><name><surname>Ojeda</surname><given-names>A.</given-names></name><name><surname>Garc&#x000ed;a-Delgado</surname><given-names>Y.</given-names></name><name><surname>Angel-Moreno</surname><given-names>A.</given-names></name><name><surname>Carranza-Rodr&#x000ed;guez</surname><given-names>C.</given-names></name><name><surname>Bellini</surname><given-names>R.</given-names></name><name><surname>Franc&#x000e8;s</surname><given-names>A.</given-names></name><name><surname>N&#x000f3;voa</surname><given-names>F.J.</given-names></name><name><surname>P&#x000e9;rez-Arellano</surname><given-names>J.L.</given-names></name></person-group><article-title>Mumps orchitis in the post-vaccine era (1967&#x02013;2009): A single-center series of 67 patients and review of clinical outcome and trends</article-title><source>Medicine</source><year>2010</year><volume>89</volume><fpage>96</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1097/MD.0b013e3181d63191</pub-id><pub-id pub-id-type="pmid">20517181</pub-id></element-citation></ref><ref id="B70-ijerph-17-01686"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname><given-names>Y.</given-names></name><name><surname>Horino</surname><given-names>K.</given-names></name><name><surname>Umetsu</surname><given-names>M.</given-names></name><name><surname>Wataya</surname><given-names>Y.</given-names></name><name><surname>Chiba</surname><given-names>S.</given-names></name></person-group><article-title>Virus excretion and antibody response in saliva in natural mumps</article-title><source>Tohoku J. Exp. Med.</source><year>1973</year><volume>111</volume><fpage>229</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1620/tjem.111.229</pub-id><pub-id pub-id-type="pmid">4598423</pub-id></element-citation></ref><ref id="B71-ijerph-17-01686"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleischer</surname><given-names>B.</given-names></name><name><surname>Kreth</surname><given-names>H.W.</given-names></name></person-group><article-title>Mumps virus replication in human lymphoid cell lines and in peripheral blood lymphocytes: Preference for T cells</article-title><source>Infect. Immun.</source><year>1982</year><volume>35</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1128/IAI.35.1.25-31.1982</pub-id><?supplied-pmid 6976327?><pub-id pub-id-type="pmid">6976327</pub-id></element-citation></ref><ref id="B72-ijerph-17-01686"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowalzik</surname><given-names>F.</given-names></name><name><surname>Faber</surname><given-names>J.</given-names></name><name><surname>Knuf</surname><given-names>M.</given-names></name></person-group><article-title>MMR and MMRV vaccines</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>5402</fpage><lpage>5407</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.07.051</pub-id><?supplied-pmid 28757060?><pub-id pub-id-type="pmid">28757060</pub-id></element-citation></ref><ref id="B73-ijerph-17-01686"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarzer</surname><given-names>S.</given-names></name><name><surname>Reibel</surname><given-names>S.</given-names></name><name><surname>Lang</surname><given-names>A.B.</given-names></name><name><surname>Struck</surname><given-names>M.M.</given-names></name><name><surname>Finkel</surname><given-names>B.</given-names></name><name><surname>Gerike</surname><given-names>E.</given-names></name><name><surname>Tischer</surname><given-names>A.</given-names></name><name><surname>Gassner</surname><given-names>M.</given-names></name><name><surname>Gl&#x000fc;ck</surname><given-names>R.</given-names></name><name><surname>St&#x000fc;ck</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines</article-title><source>Vaccine</source><year>1998</year><volume>16</volume><fpage>298</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(97)00174-6</pub-id><pub-id pub-id-type="pmid">9607046</pub-id></element-citation></ref><ref id="B74-ijerph-17-01686"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fescharek</surname><given-names>R.</given-names></name><name><surname>Quast</surname><given-names>U.</given-names></name><name><surname>Maass</surname><given-names>G.</given-names></name><name><surname>Merkle</surname><given-names>W.</given-names></name><name><surname>Schwarz</surname><given-names>S.</given-names></name></person-group><article-title>Measles-mumps vaccination in the FRG: An empirical analysis after 14 years of use. I. Efficacy and analysis of vaccine failures</article-title><source>Vaccine</source><year>1990</year><volume>8</volume><fpage>333</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(90)90090-9</pub-id><pub-id pub-id-type="pmid">2396472</pub-id></element-citation></ref><ref id="B75-ijerph-17-01686"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feiterna-Sperling</surname><given-names>C.</given-names></name><name><surname>Br&#x000f6;nnimann</surname><given-names>R.</given-names></name><name><surname>Tischer</surname><given-names>A.</given-names></name><name><surname>Stettler</surname><given-names>P.</given-names></name><name><surname>Durrer</surname><given-names>P.</given-names></name><name><surname>Gaedicke</surname><given-names>G.</given-names></name></person-group><article-title>Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children</article-title><source>Pediatr. Infect. Dis. J.</source><year>2005</year><volume>24</volume><fpage>1083</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1097/01.inf.0000183746.92218.f9</pub-id><pub-id pub-id-type="pmid">16371870</pub-id></element-citation></ref><ref id="B76-ijerph-17-01686"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname><given-names>K.M.</given-names></name><name><surname>Hviid</surname><given-names>A.</given-names></name><name><surname>Vestergaard</surname><given-names>M.</given-names></name><name><surname>Schendel</surname><given-names>D.</given-names></name><name><surname>Wohlfahrt</surname><given-names>J.</given-names></name><name><surname>Thorsen</surname><given-names>P.</given-names></name><name><surname>Olsen</surname><given-names>J.</given-names></name><name><surname>Melbye</surname><given-names>M.</given-names></name></person-group><article-title>A population-based study of measles, mumps, and rubella vaccination and autism</article-title><source>N. Engl. J. Med.</source><year>2002</year><volume>347</volume><fpage>1477</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa021134</pub-id><pub-id pub-id-type="pmid">12421889</pub-id></element-citation></ref><ref id="B77-ijerph-17-01686"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardemil</surname><given-names>C.V.</given-names></name><name><surname>Dahl</surname><given-names>R.M.</given-names></name><name><surname>James</surname><given-names>L.</given-names></name><name><surname>Wannemuehler</surname><given-names>K.</given-names></name><name><surname>Gary</surname><given-names>H.E.</given-names></name><name><surname>Shah</surname><given-names>M.</given-names></name><name><surname>Marin</surname><given-names>M.</given-names></name><name><surname>Riley</surname><given-names>J.</given-names></name><name><surname>Feikin</surname><given-names>D.R.</given-names></name><name><surname>Patel</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>947</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1703309</pub-id><pub-id pub-id-type="pmid">28877026</pub-id></element-citation></ref><ref id="B78-ijerph-17-01686"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giaquinto</surname><given-names>C.</given-names></name><name><surname>Gabutti</surname><given-names>G.</given-names></name><name><surname>Baldo</surname><given-names>V.</given-names></name><name><surname>Villa</surname><given-names>M.</given-names></name><name><surname>Tramontan</surname><given-names>L.</given-names></name><name><surname>Raccanello</surname><given-names>N.</given-names></name><name><surname>Russo</surname><given-names>F.</given-names></name><name><surname>Poma</surname><given-names>C.</given-names></name><name><surname>Scamarcia</surname><given-names>A.</given-names></name><name><surname>Cantarutti</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy</article-title><source>BMC Infect. Dis.</source><year>2018</year><volume>18</volume><elocation-id>103</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-018-3017-9</pub-id><pub-id pub-id-type="pmid">29506477</pub-id></element-citation></ref><ref id="B79-ijerph-17-01686"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buynak</surname><given-names>E.B.</given-names></name><name><surname>Hilleman</surname><given-names>M.R.</given-names></name></person-group><article-title>Live attenuated mumps virus vaccine. 1. Vaccine development</article-title><source>Proc. Soc. Exp. Biol. Med.</source><year>1966</year><volume>123</volume><fpage>768</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.3181/00379727-123-31599</pub-id><pub-id pub-id-type="pmid">4163620</pub-id></element-citation></ref><ref id="B80-ijerph-17-01686"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>M.C.</given-names></name><name><surname>Dutta</surname><given-names>A.</given-names></name><name><surname>Weinberger</surname><given-names>C.</given-names></name><name><surname>Plotkin</surname><given-names>S.A.</given-names></name></person-group><article-title>Mumps vaccine virus strains and aseptic meningitis</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>7037</fpage><lpage>7045</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.06.049</pub-id><pub-id pub-id-type="pmid">16884835</pub-id></element-citation></ref><ref id="B81-ijerph-17-01686"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonville-Bera</surname><given-names>A.</given-names></name><name><surname>Autret</surname><given-names>E.</given-names></name><name><surname>Galy-Eyraud</surname><given-names>C.</given-names></name><name><surname>Hessel</surname><given-names>L.</given-names></name></person-group><article-title>Aseptic meningitis following mumps vaccine. A retrospective survey by the French Regional Pharmacovigilance centres and by Pasteur-M&#x000e9;rieux S&#x000e9;rums and Vaccines. Pharmacoepidemiol</article-title><source>Drug Saf.</source><year>1996</year><volume>5</volume><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1099-1557(199601)5:1&#x0003c;33::AID-PDS210&#x0003e;3.0.CO;2-7</pub-id></element-citation></ref><ref id="B82-ijerph-17-01686"><label>82.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO Expert Committee on Biological Standardization</collab></person-group><source>Forty Third Report</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>1994</year></element-citation></ref><ref id="B83-ijerph-17-01686"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuter</surname><given-names>B.J.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Wiedmann</surname><given-names>R.T.</given-names></name><name><surname>Hartzel</surname><given-names>J.</given-names></name><name><surname>Musey</surname><given-names>L.</given-names></name></person-group><article-title>Safety and Immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009</article-title><source>Pediatr. Infect. Dis. J.</source><year>2016</year><volume>35</volume><fpage>1011</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000001241</pub-id><?supplied-pmid 27254037?><pub-id pub-id-type="pmid">27254037</pub-id></element-citation></ref><ref id="B84-ijerph-17-01686"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahlgren</surname><given-names>K.</given-names></name></person-group><article-title>Two doses of MMR vaccine&#x02014;Sufficient to eradicate measles, mumps and rubella?</article-title><source>Scand. J. Soc. Med.</source><year>1988</year><volume>6</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1177/140349488801600301</pub-id><?supplied-pmid 3057621?><pub-id pub-id-type="pmid">3057621</pub-id></element-citation></ref><ref id="B85-ijerph-17-01686"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broliden</surname><given-names>K.</given-names></name><name><surname>Abreu</surname><given-names>E.R.</given-names></name><name><surname>Arneborn</surname><given-names>M.</given-names></name><name><surname>B&#x000f6;ttiger</surname><given-names>M.</given-names></name></person-group><article-title>Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two&#x02014;Dose immunization programme</article-title><source>Vaccine</source><year>1998</year><volume>16</volume><fpage>323</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(97)88332-6</pub-id><pub-id pub-id-type="pmid">9607050</pub-id></element-citation></ref><ref id="B86-ijerph-17-01686"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidkin</surname><given-names>I.</given-names></name><name><surname>Valle</surname><given-names>M.</given-names></name><name><surname>Julkunen</surname><given-names>I.</given-names></name></person-group><article-title>Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination: A nine-year follow-up</article-title><source>Vaccine</source><year>1995</year><volume>13</volume><fpage>1617</fpage><lpage>1622</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(95)00064-8</pub-id><pub-id pub-id-type="pmid">8578851</pub-id></element-citation></ref><ref id="B87-ijerph-17-01686"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrenkranz</surname><given-names>N.J.</given-names></name><name><surname>Ventura</surname><given-names>A.K.</given-names></name><name><surname>Medler</surname><given-names>E.M.</given-names></name><name><surname>Jackson</surname><given-names>J.E.</given-names></name><name><surname>Kenny</surname><given-names>M.T.</given-names></name></person-group><article-title>Clinical evaluation of a new measles&#x02013; mumps&#x02013;rubella combined live virus vaccine in the Dominican Republic</article-title><source>Bull. World Health Organ.</source><year>1975</year><volume>52</volume><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">764997</pub-id></element-citation></ref><ref id="B88-ijerph-17-01686"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briss</surname><given-names>P.A.</given-names></name><name><surname>Fehrs</surname><given-names>L.J.</given-names></name><name><surname>Parker</surname><given-names>R.A.</given-names></name><name><surname>Wright</surname><given-names>P.F.</given-names></name><name><surname>Sannella</surname><given-names>E.C.</given-names></name><name><surname>Hutcheson</surname><given-names>R.H.</given-names></name><name><surname>Schaffner</surname><given-names>W.</given-names></name></person-group><article-title>Sustained transmission of mumps in a highly vaccinated population: Assessment of primary vaccine failure and waning vaccine&#x02013;induced immunity</article-title><source>J. Infect. Dis.</source><year>1994</year><volume>169</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1093/infdis/169.1.77</pub-id><pub-id pub-id-type="pmid">8277201</pub-id></element-citation></ref><ref id="B89-ijerph-17-01686"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>M.</given-names></name><name><surname>Quinlisk</surname><given-names>P.</given-names></name><name><surname>Weigel</surname><given-names>A.</given-names></name><name><surname>Riley</surname><given-names>J.</given-names></name><name><surname>James</surname><given-names>L.</given-names></name><name><surname>Patterson</surname><given-names>J.</given-names></name><name><surname>Hickman</surname><given-names>C.</given-names></name><name><surname>Rota</surname><given-names>P.A.</given-names></name><name><surname>Stewart</surname><given-names>R.</given-names></name><name><surname>Clemmons</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Mumps Outbreak in a Highly Vaccinated University-Affiliated Setting Before and After a Measles-Mumps-Rubella Vaccination Campaign-Iowa, July 2015&#x02013;May 2016</article-title><source>Clin. Infect. Dis.</source><year>2018</year><volume>66</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1093/cid/cix718</pub-id><pub-id pub-id-type="pmid">29020324</pub-id></element-citation></ref><ref id="B90-ijerph-17-01686"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilleman</surname><given-names>M.R.</given-names></name><name><surname>Weibel</surname><given-names>R.E.</given-names></name><name><surname>Buynak</surname><given-names>E.B.</given-names></name><name><surname>Stokes</surname><given-names>J.</given-names><suffix>Jr.</suffix></name><name><surname>Whitman</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation</article-title><source>N. Engl. J. Med.</source><year>1967</year><volume>276</volume><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1056/NEJM196702022760502</pub-id><pub-id pub-id-type="pmid">6016061</pub-id></element-citation></ref><ref id="B91-ijerph-17-01686"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pugh</surname><given-names>R.N.</given-names></name><name><surname>Akinosi</surname><given-names>B.</given-names></name><name><surname>Pooransingh</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>J.</given-names></name><name><surname>Grant</surname><given-names>S.</given-names></name><name><surname>Livesley</surname><given-names>E.</given-names></name><name><surname>Linnane</surname><given-names>J.</given-names></name><name><surname>Ramaiah</surname><given-names>S.</given-names></name></person-group><article-title>An outbreak of mumps in the metropolitan area of Walsall, UK</article-title><source>Int. J. Infect. Dis.</source><year>2002</year><volume>6</volume><fpage>283</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/S1201-9712(02)90162-1</pub-id><pub-id pub-id-type="pmid">12718822</pub-id></element-citation></ref><ref id="B92-ijerph-17-01686"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>May</surname><given-names>M.</given-names></name><name><surname>Rieder</surname><given-names>C.A.</given-names></name><name><surname>Rowe</surname><given-names>R.</given-names></name></person-group><article-title>Emergent lineages of mumps virus suggest the need for a polyvalent vaccine</article-title><source>Int. J. Infect. Dis.</source><year>2018</year><volume>66</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2017.09.024</pub-id><?supplied-pmid 28987391?><pub-id pub-id-type="pmid">28987391</pub-id></element-citation></ref><ref id="B93-ijerph-17-01686"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention (CDC)</collab></person-group><article-title>Mumps outbreak at a summer camp&#x02014;New York, 2005</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2006</year><volume>55</volume><fpage>175</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">16498381</pub-id></element-citation></ref><ref id="B94-ijerph-17-01686"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dom&#x000ed;nguez</surname><given-names>A.</given-names></name><name><surname>Torner</surname><given-names>N.</given-names></name><name><surname>Castilla</surname><given-names>J.</given-names></name><name><surname>Batalla</surname><given-names>J.</given-names></name><name><surname>Godoy</surname><given-names>P.</given-names></name><name><surname>Guevara</surname><given-names>M.</given-names></name><name><surname>Carnicer</surname><given-names>D.</given-names></name><name><surname>Cayl&#x000e0;</surname><given-names>J.</given-names></name><name><surname>Rius</surname><given-names>C.</given-names></name><name><surname>Jans&#x000e0;</surname><given-names>J.M.</given-names></name></person-group><article-title>Mumps vaccine effectiveness in highly immunized populations</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>3567</fpage><lpage>3570</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.02.107</pub-id><?supplied-pmid 20226249?><pub-id pub-id-type="pmid">20226249</pub-id></element-citation></ref><ref id="B95-ijerph-17-01686"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>S.</given-names></name><name><surname>Shinefield</surname><given-names>H.</given-names></name><name><surname>Ray</surname><given-names>P.</given-names></name><name><surname>Lewis</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Glasser</surname><given-names>J.</given-names></name><name><surname>Hadler</surname><given-names>S.</given-names></name><name><surname>Hardy</surname><given-names>J.</given-names></name><name><surname>Rhodes</surname><given-names>P.</given-names></name><name><surname>Swint</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Risk of hospitalization because of aseptic meningitis after measles&#x02013;mumps&#x02013;rubella vaccination in one- to two-year-old children: An analysis of the Vaccine Safety Datalink (VSD) Project</article-title><source>Pediatr. Infect. Dis. J.</source><year>1997</year><volume>16</volume><fpage>500</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1097/00006454-199705000-00009</pub-id><pub-id pub-id-type="pmid">9154545</pub-id></element-citation></ref><ref id="B96-ijerph-17-01686"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reisinger</surname><given-names>K.S.</given-names></name><name><surname>Brown</surname><given-names>M.L.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Sullivan</surname><given-names>B.J.</given-names></name><name><surname>Marshall</surname><given-names>G.S.</given-names></name><name><surname>Nauert</surname><given-names>B.</given-names></name><name><surname>Matson</surname><given-names>D.O.</given-names></name><name><surname>Silas</surname><given-names>P.E.</given-names></name><name><surname>Sch&#x000f6;del</surname><given-names>F.</given-names></name><name><surname>Gress</surname><given-names>J.O.</given-names></name><etal/></person-group><article-title>A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax</article-title><source>Pediatrics</source><year>2006</year><volume>117</volume><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1542/peds.2005-0092</pub-id><pub-id pub-id-type="pmid">16452343</pub-id></element-citation></ref><ref id="B97-ijerph-17-01686"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S.J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Xiong</surname><given-names>Y.Q.</given-names></name><name><surname>Yao</surname><given-names>A.L.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name></person-group><article-title>Combination measles-mumps-rubella-varicella vaccine in healthy children: A Systematic Review and Meta-analysis of Immunogenicity and Safety</article-title><source>Medicine</source><year>2015</year><volume>94</volume><fpage>e1721</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000001721</pub-id><pub-id pub-id-type="pmid">26554769</pub-id></element-citation></ref><ref id="B98-ijerph-17-01686"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tillieux</surname><given-names>S.L.</given-names></name><name><surname>Halsey</surname><given-names>W.S.</given-names></name><name><surname>Sathe</surname><given-names>G.M.</given-names></name><name><surname>Vassilev</surname><given-names>V.</given-names></name></person-group><article-title>Comparative analysis of the complete neucleotide sequences of measles, mumps, and rubella strain genomes comtained in Priorix-Tetra<sup>TM</sup> and ProQuad<sup>TM</sup> live attenuated combined vaccines</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>2265</fpage><lpage>2273</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.112</pub-id><pub-id pub-id-type="pmid">19428841</pub-id></element-citation></ref><ref id="B99-ijerph-17-01686"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>T.</given-names></name><name><surname>Eda</surname><given-names>M.</given-names></name><name><surname>Hirano</surname><given-names>M.</given-names></name><name><surname>Goto</surname><given-names>W.</given-names></name></person-group><article-title>Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: A randomized phase I/II clinical trial</article-title><source>Hum. Vaccin. Immunother.</source><year>2019</year><volume>15</volume><fpage>1139</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1080/21645515.2019.1578591</pub-id><pub-id pub-id-type="pmid">30724658</pub-id></element-citation></ref><ref id="B100-ijerph-17-01686"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smorodintsev</surname><given-names>A.A.</given-names></name><name><surname>Nasibov</surname><given-names>M.N.</given-names></name><name><surname>Jakovleva</surname><given-names>N.V.</given-names></name></person-group><article-title>Experience with live rubella virus vaccine combined with live vaccines against measles and mumps</article-title><source>Bull. World Health Organ.</source><year>1970</year><volume>42</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">5310140</pub-id></element-citation></ref><ref id="B101-ijerph-17-01686"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cizman</surname><given-names>M.</given-names></name><name><surname>Mozetic</surname><given-names>M.</given-names></name><name><surname>Radescek-Rakar</surname><given-names>R.</given-names></name><name><surname>Pleterski-Rigler</surname><given-names>D.</given-names></name><name><surname>Susec-Michieli</surname><given-names>M.</given-names></name></person-group><article-title>Aseptic meningitis after vaccination against measles and mumps</article-title><source>Pediatr. Infect. Dis. J.</source><year>1989</year><volume>8</volume><fpage>302</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">2726323</pub-id></element-citation></ref><ref id="B102-ijerph-17-01686"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>M.</given-names></name><name><surname>Welsz-Malecek</surname><given-names>R.</given-names></name><name><surname>Mesko-Prejac</surname><given-names>M.</given-names></name><name><surname>Radman</surname><given-names>V.</given-names></name><name><surname>Juzbasic</surname><given-names>M.</given-names></name><name><surname>Rajninger-Miholic</surname><given-names>M.</given-names></name><name><surname>Prislin-Musklic</surname><given-names>M.</given-names></name><name><surname>Dobrovsak-Sourek</surname><given-names>V.</given-names></name><name><surname>Smerdel</surname><given-names>S.</given-names></name><name><surname>Stainer</surname><given-names>D.W.</given-names></name></person-group><article-title>Mumps vaccine L-Zagreb, prepared in chick fibroblasts: I. production and field trials</article-title><source>J. Biol. Stand.</source><year>1989</year><volume>17</volume><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/0092-1157(89)90031-0</pub-id><pub-id pub-id-type="pmid">2646300</pub-id></element-citation></ref><ref id="B103-ijerph-17-01686"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhargava</surname><given-names>I.</given-names></name><name><surname>Chhaparwal</surname><given-names>B.C.</given-names></name><name><surname>Phadke</surname><given-names>M.A.</given-names></name><name><surname>Irani</surname><given-names>S.F.</given-names></name><name><surname>Chhaparwal</surname><given-names>D.</given-names></name><name><surname>Dhorje</surname><given-names>S.</given-names></name><name><surname>Maheshwari</surname><given-names>C.P.</given-names></name></person-group><article-title>Immunogenicity and reactogenicity of indigenously produced MMR vaccine</article-title><source>Indian Pediatr.</source><year>1995</year><volume>32</volume><fpage>983</fpage><lpage>988</lpage><?supplied-pmid 8935261?><pub-id pub-id-type="pmid">8935261</pub-id></element-citation></ref><ref id="B104-ijerph-17-01686"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tesovic</surname><given-names>G.</given-names></name><name><surname>Begovac</surname><given-names>J.</given-names></name><name><surname>Bace</surname><given-names>A.</given-names></name></person-group><article-title>Aseptic meningitis after measles, mumps, and rubella vaccine</article-title><source>Lancet</source><year>1993</year><volume>341</volume><fpage>1541</fpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)90684-9</pub-id></element-citation></ref><ref id="B105-ijerph-17-01686"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gl&#x000fc;ck</surname><given-names>R.</given-names></name><name><surname>Hoskins</surname><given-names>J.M.</given-names></name><name><surname>Wegmann</surname><given-names>A.</given-names></name><name><surname>Just</surname><given-names>M.</given-names></name><name><surname>Germanier</surname><given-names>R.</given-names></name></person-group><article-title>Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells</article-title><source>Dev. Biol. Stand.</source><year>1986</year><volume>65</volume><fpage>29</fpage><lpage>35</lpage><?supplied-pmid 3556774?><pub-id pub-id-type="pmid">3556774</pub-id></element-citation></ref><ref id="B106-ijerph-17-01686"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vesikari</surname><given-names>T.</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>F.E.</given-names></name><name><surname>Simoen</surname><given-names>E.</given-names></name><name><surname>Florent</surname><given-names>G.</given-names></name><name><surname>Ala-Laurila</surname><given-names>E.L.</given-names></name><name><surname>Heikkinen</surname><given-names>A.</given-names></name><name><surname>Kuusinen</surname><given-names>H.</given-names></name><name><surname>Terho</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation in young children of the Urabe Am 9 strain of live attenuated mumps vaccine in comparison with the Jeryl Lynn strain</article-title><source>Acta Paediatr. Scand.</source><year>1983</year><volume>72</volume><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/j.1651-2227.1983.tb09660.x</pub-id><?supplied-pmid 6344550?><pub-id pub-id-type="pmid">6344550</pub-id></element-citation></ref><ref id="B107-ijerph-17-01686"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>G.</given-names></name><name><surname>Goh</surname><given-names>K.T.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Chew</surname><given-names>S.K.</given-names></name></person-group><article-title>Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population</article-title><source>J. Infect.</source><year>2005</year><volume>51</volume><fpage>294</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2004.10.001</pub-id><?supplied-pmid 16291282?><pub-id pub-id-type="pmid">16291282</pub-id></element-citation></ref><ref id="B108-ijerph-17-01686"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>J.A.</given-names></name><name><surname>Cordeiro</surname><given-names>M.</given-names></name><name><surname>Afzal</surname><given-names>M.A.</given-names></name><name><surname>Freitas</surname><given-names>M.G.</given-names></name><name><surname>Morgado</surname><given-names>M.R.</given-names></name><name><surname>Silva</surname><given-names>J.L.</given-names></name><name><surname>Nunes</surname><given-names>L.M.</given-names></name><name><surname>Lima</surname><given-names>M.G.</given-names></name><name><surname>Avilez</surname><given-names>F.</given-names></name></person-group><article-title>Mumps epidemic in Portugal despite high vaccine coverage&#x02014;Preliminary report</article-title><source>Eurosurveillance</source><year>1996</year><volume>1</volume><fpage>25</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.2807/esm.01.04.00160-en</pub-id></element-citation></ref><ref id="B109-ijerph-17-01686"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>J.L.</given-names></name><name><surname>Zwahlen</surname><given-names>M.</given-names></name><name><surname>Feuz</surname><given-names>M.</given-names></name><name><surname>Matter</surname><given-names>H.C.</given-names></name></person-group><article-title>Swiss Sentinel Surveillance Network. Comparison of the effectiveness of two mumps vaccines during an outbreak in Switzerland in 1999 and 2000: A case-cohort study</article-title><source>Eur. J. Epidemiol.</source><year>2003</year><volume>18</volume><fpage>569</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1023/A:1024698900332</pub-id><pub-id pub-id-type="pmid">12908724</pub-id></element-citation></ref><ref id="B110-ijerph-17-01686"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>John</surname><given-names>T.J.</given-names></name><name><surname>Cherian</surname><given-names>T.</given-names></name><name><surname>Raghupathy</surname><given-names>P.</given-names></name></person-group><article-title>Immune response to measles, mumps and rubella vaccine at 9, 12 and 15 months of age</article-title><source>Indian J. Med. Res.</source><year>1994</year><volume>100</volume><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">7851964</pub-id></element-citation></ref><ref id="B111-ijerph-17-01686"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L.M.</given-names></name><name><surname>Lee</surname><given-names>C.Y.</given-names></name><name><surname>Hsu</surname><given-names>C.Y.</given-names></name><name><surname>Huang</surname><given-names>S.S.</given-names></name><name><surname>Kao</surname><given-names>C.L.</given-names></name><name><surname>Wu</surname><given-names>F.F.</given-names></name><name><surname>Lee</surname><given-names>C.C.</given-names></name><name><surname>Chang</surname><given-names>H.S.</given-names></name><name><surname>Huang</surname><given-names>L.Y.</given-names></name></person-group><article-title>Effect of monovalent measles and trivalent measles&#x02013;mumps&#x02013;rubella vaccines at various ages and concurrent administration with hepatitis B vaccine</article-title><source>Pediatr. Infect. Dis. J.</source><year>1990</year><volume>9</volume><fpage>461</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1097/00006454-199007000-00002</pub-id><pub-id pub-id-type="pmid">2371079</pub-id></element-citation></ref><ref id="B112-ijerph-17-01686"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>E.</given-names></name><name><surname>Hill</surname><given-names>A.</given-names></name><name><surname>Morgan-Capner</surname><given-names>P.</given-names></name><name><surname>Forsey</surname><given-names>T.</given-names></name><name><surname>Rush</surname><given-names>M.</given-names></name></person-group><article-title>Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines</article-title><source>Vaccine</source><year>1995</year><volume>13</volume><fpage>799</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(94)00086-3</pub-id><pub-id pub-id-type="pmid">7483800</pub-id></element-citation></ref><ref id="B113-ijerph-17-01686"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>E.G.</given-names></name><name><surname>Furesz</surname><given-names>J.</given-names></name><name><surname>Dimock</surname><given-names>K.</given-names></name><name><surname>Yarosh</surname><given-names>W.</given-names></name><name><surname>Contreras</surname><given-names>G.</given-names></name></person-group><article-title>Nucleotide sequence analysis of Urab mumps vaccine strain that caused meningitis in vaccine recipients</article-title><source>Vaccine</source><year>1991</year><volume>9</volume><fpage>840</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(91)90223-S</pub-id><pub-id pub-id-type="pmid">1759507</pub-id></element-citation></ref><ref id="B114-ijerph-17-01686"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>E.G.</given-names></name><name><surname>Dimock</surname><given-names>K.</given-names></name><name><surname>Wright</surname><given-names>K.E.</given-names></name></person-group><article-title>The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease</article-title><source>J. Infect. Dis.</source><year>1996</year><volume>174</volume><fpage>619</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1093/infdis/174.3.619</pub-id><?supplied-pmid 8769623?><pub-id pub-id-type="pmid">8769623</pub-id></element-citation></ref><ref id="B115-ijerph-17-01686"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulianne</surname><given-names>N.</given-names></name><name><surname>De Serres</surname><given-names>G.</given-names></name><name><surname>Ratnam</surname><given-names>S.</given-names></name><name><surname>Ward</surname><given-names>B.J.</given-names></name><name><surname>Joly</surname><given-names>J.R.</given-names></name><name><surname>Duval</surname><given-names>B.</given-names></name></person-group><article-title>Measles, mumps, and rubella antibodies in children 5&#x02013;6 years after immunization: Effect of vaccine type and age of vaccination</article-title><source>Vaccine</source><year>1995</year><volume>13</volume><fpage>1611</fpage><lpage>1616</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(95)00098-L</pub-id><pub-id pub-id-type="pmid">8578850</pub-id></element-citation></ref><ref id="B116-ijerph-17-01686"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dourado</surname><given-names>I.</given-names></name><name><surname>Cunha</surname><given-names>S.</given-names></name><name><surname>Teixeira</surname><given-names>M.G.</given-names></name><name><surname>Farrington</surname><given-names>C.P.</given-names></name><name><surname>Melo</surname><given-names>A.</given-names></name><name><surname>Lucena</surname><given-names>R.</given-names></name><name><surname>Barreto</surname><given-names>M.L.</given-names></name></person-group><article-title>Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: Implications for immunization programs</article-title><source>Am. J. Epidemiol.</source><year>2000</year><volume>151</volume><fpage>524</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a010239</pub-id><?supplied-pmid 10707922?><pub-id pub-id-type="pmid">10707922</pub-id></element-citation></ref><ref id="B117-ijerph-17-01686"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amexis</surname><given-names>G.</given-names></name><name><surname>Fineschi</surname><given-names>N.</given-names></name><name><surname>Chumakov</surname><given-names>K.</given-names></name></person-group><article-title>Correlation of genetic variability with safety of mumps vaccine Urabe AM9 strain</article-title><source>Virology</source><year>2001</year><volume>287</volume><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1006/viro.2001.1009</pub-id><pub-id pub-id-type="pmid">11504558</pub-id></element-citation></ref><ref id="B118-ijerph-17-01686"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furesz</surname><given-names>J.</given-names></name><name><surname>Contreras</surname><given-names>G.</given-names></name></person-group><article-title>Vaccine&#x02013;related mumps meningitis&#x02014;Canada</article-title><source>Can. Dis. Wkly. Rep.</source><year>1990</year><volume>16</volume><fpage>253</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">2285950</pub-id></element-citation></ref><ref id="B119-ijerph-17-01686"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>E.</given-names></name><name><surname>Goldacre</surname><given-names>M.</given-names></name><name><surname>Pugh</surname><given-names>S.</given-names></name><name><surname>Colville</surname><given-names>A.</given-names></name><name><surname>Farrington</surname><given-names>P.</given-names></name><name><surname>Flower</surname><given-names>A.</given-names></name><name><surname>Nash</surname><given-names>J.</given-names></name><name><surname>MacFarlane</surname><given-names>L.</given-names></name><name><surname>Tettmar</surname><given-names>R.</given-names></name></person-group><article-title>Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children</article-title><source>Lancet</source><year>1993</year><volume>341</volume><fpage>979</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)91069-X</pub-id><pub-id pub-id-type="pmid">8096942</pub-id></element-citation></ref><ref id="B120-ijerph-17-01686"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiura</surname><given-names>A.</given-names></name><name><surname>Yamada</surname><given-names>A.</given-names></name></person-group><article-title>Aseptic meningitis as a complication of mumps vaccination</article-title><source>Pediatr. Infect. Dis. J.</source><year>1991</year><volume>10</volume><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1097/00006454-199103000-00008</pub-id><pub-id pub-id-type="pmid">2041668</pub-id></element-citation></ref><ref id="B121-ijerph-17-01686"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>K.</given-names></name><name><surname>Miyazaki</surname><given-names>C.</given-names></name><name><surname>Hidaka</surname><given-names>Y.</given-names></name><name><surname>Okada</surname><given-names>K.</given-names></name><name><surname>Kusuhara</surname><given-names>K.</given-names></name><name><surname>Kadoya</surname><given-names>R.</given-names></name></person-group><article-title>Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan</article-title><source>Lancet</source><year>1995</year><volume>346</volume><fpage>701</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(95)92311-X</pub-id></element-citation></ref><ref id="B122-ijerph-17-01686"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>S.A.</given-names></name><name><surname>Link</surname><given-names>M.A.</given-names></name><name><surname>Sauder</surname><given-names>C.J.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Ngo</surname><given-names>L.</given-names></name><name><surname>Rima</surname><given-names>B.K.</given-names></name><name><surname>Duprex</surname><given-names>W.P.</given-names></name></person-group><article-title>Recent mumps outbreaks in vaccinated populations: No evidence of immune escape</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>615</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1128/JVI.06125-11</pub-id><?supplied-pmid 22072778?><pub-id pub-id-type="pmid">22072778</pub-id></element-citation></ref><ref id="B123-ijerph-17-01686"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rota</surname><given-names>J.S.</given-names></name><name><surname>Rosen</surname><given-names>J.B.</given-names></name><name><surname>Doll</surname><given-names>M.K.</given-names></name><name><surname>McNall</surname><given-names>R.J.</given-names></name><name><surname>McGrew</surname><given-names>M.</given-names></name><name><surname>Williams</surname><given-names>N.</given-names></name><name><surname>Lopareva</surname><given-names>E.N.</given-names></name><name><surname>Barskey</surname><given-names>A.E.</given-names></name><name><surname>Punsalang</surname><given-names>A.</given-names><suffix>Jr.</suffix></name><name><surname>Rota</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Comparison of the Sensitivity of Laboratory Diagnostic Methods from a Well-Characterized Outbreak of Mumps in New York City in 2009</article-title><source>Clin. Vaccine Immunol.</source><year>2013</year><volume>20</volume><fpage>391</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1128/CVI.00660-12</pub-id><?supplied-pmid 23324519?><pub-id pub-id-type="pmid">23324519</pub-id></element-citation></ref><ref id="B124-ijerph-17-01686"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortese</surname><given-names>M.M.</given-names></name><name><surname>Jordan</surname><given-names>H.T.</given-names></name><name><surname>Curns</surname><given-names>A.T.</given-names></name><name><surname>Quinlan</surname><given-names>P.A.</given-names></name><name><surname>Ens</surname><given-names>K.A.</given-names></name><name><surname>Denning</surname><given-names>P.M.</given-names></name><name><surname>Dayan</surname><given-names>G.H.</given-names></name></person-group><article-title>Mumps vaccine performance among university students during a mumps outbreak</article-title><source>Clin. Infect. Dis.</source><year>2008</year><volume>46</volume><fpage>1172</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1086/529141</pub-id><?supplied-pmid 18444852?><pub-id pub-id-type="pmid">18444852</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijerph-17-01686-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow chart of article searching procedures.</p></caption><graphic xlink:href="ijerph-17-01686-g001"/></fig><table-wrap id="ijerph-17-01686-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">ijerph-17-01686-t001_Table 1</object-id><label>Table 1</label><caption><p>Comparison of mumps incidence between the pre-vaccine and post-vaccine eras among some countries.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pre-vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Postvaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Country [reference]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Annual incidence (per 100,000)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Annual incidence (per 100,000)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA [<xref rid="B6-ijerph-17-01686" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1967</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1993</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Denmark [<xref rid="B4-ijerph-17-01686" ref-type="bibr">4</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1979</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">726</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Finland [<xref rid="B11-ijerph-17-01686" ref-type="bibr">11</xref>,<xref rid="B12-ijerph-17-01686" ref-type="bibr">12</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1982</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Slovenia [<xref rid="B4-ijerph-17-01686" ref-type="bibr">4</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1979</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">410</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Croatia [<xref rid="B9-ijerph-17-01686" ref-type="bibr">9</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1985</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">France [<xref rid="B14-ijerph-17-01686" ref-type="bibr">14</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1986</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">859</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">England and Wales [<xref rid="B10-ijerph-17-01686" ref-type="bibr">10</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1985</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eastern Germany [<xref rid="B13-ijerph-17-01686" ref-type="bibr">13</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1986</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">155</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.62</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Israel [<xref rid="B15-ijerph-17-01686" ref-type="bibr">15</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1985</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thailand [<xref rid="B16-ijerph-17-01686" ref-type="bibr">16</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1996</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20&#x02013;70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1997</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10&#x02013;30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Korea [<xref rid="B18-ijerph-17-01686" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1961</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;15,000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1981</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Australia [<xref rid="B19-ijerph-17-01686" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1969</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59,000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Taiwan [<xref rid="B20-ijerph-17-01686" ref-type="bibr">20</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1992</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2006</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr></tbody></table></table-wrap><table-wrap id="ijerph-17-01686-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">ijerph-17-01686-t002_Table 2</object-id><label>Table 2</label><caption><p>Composition of measles-mumps-rubella (MMR) vaccines [<xref rid="B72-ijerph-17-01686" ref-type="bibr">72</xref>,<xref rid="B73-ijerph-17-01686" ref-type="bibr">73</xref>,<xref rid="B74-ijerph-17-01686" ref-type="bibr">74</xref>,<xref rid="B75-ijerph-17-01686" ref-type="bibr">75</xref>,<xref rid="B76-ijerph-17-01686" ref-type="bibr">76</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Types of vaccines</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variables</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Triviraten</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MMR II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morupar</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Priorix</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trimovax </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Company</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Berna</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Merck</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sanofi Aventis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GlaxoSmithKline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sanofi Pasteur</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Measles</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Strain</td><td align="left" valign="middle" rowspan="1" colspan="1">Edmonston-Zagreb,</td><td align="left" valign="middle" rowspan="1" colspan="1">Enders Edmonston,</td><td align="left" valign="middle" rowspan="1" colspan="1">Schwarz,</td><td align="left" valign="middle" rowspan="1" colspan="1">Schwarz,</td><td align="left" valign="middle" rowspan="1" colspan="1">Schwarz,</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strength</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 TCID<sub>50</sub>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 TCID<sub>50</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 TCID<sub>50</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 TCID<sub>50</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 TCID<sub>50</sub></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mumps</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Strain</td><td align="left" valign="middle" rowspan="1" colspan="1">Rubini</td><td align="left" valign="middle" rowspan="1" colspan="1">Jeryl Lynn</td><td align="left" valign="middle" rowspan="1" colspan="1">Urabe AM9</td><td align="left" valign="middle" rowspan="1" colspan="1">RIT 4385</td><td align="left" valign="middle" rowspan="1" colspan="1">Urabe AM9</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strength</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;5000 TCID<sub>50</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;20,000 TCID<sub>50</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;5000 TCID<sub>50</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;5000 TCID<sub>50</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;5000 TCID<sub>50</sub></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Rubella</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Strain</td><td align="left" valign="middle" rowspan="1" colspan="1">Wistar RA 27/3</td><td align="left" valign="middle" rowspan="1" colspan="1">Wistar RA 27/3</td><td align="left" valign="middle" rowspan="1" colspan="1">Wistar RA 27/3</td><td align="left" valign="middle" rowspan="1" colspan="1">Wistar RA 27/3</td><td align="left" valign="middle" rowspan="1" colspan="1">Wistar RA 27/3</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strength</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 TCID<sub>50</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 TCID<sub>50</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 TCID<sub>50</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 TCID<sub>50</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 TCID<sub>50</sub></td></tr></tbody></table><table-wrap-foot><fn><p>MMR: measles, mumps, rubella; TCID<sub>50</sub>: tissue culture infective dose 50%.</p></fn></table-wrap-foot></table-wrap><table-wrap id="ijerph-17-01686-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">ijerph-17-01686-t003_Table 3</object-id><label>Table 3</label><caption><p>Composition of MMRV vaccines [<xref rid="B76-ijerph-17-01686" ref-type="bibr">76</xref>,<xref rid="B78-ijerph-17-01686" ref-type="bibr">78</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Types of </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">vaccines</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variables</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Priorix-Tetra (GlaxoSmithKline)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ProQuad (Merck)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Formulation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lyophilized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lyophilized</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diluent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Water for injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Water for injection</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Excipients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amino acids, lactose (anhydrous), mannitol and sorbitol as stabilizers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorbitol, sodium phosphate, sucrose, sodium chloride, hydrolyzed gelatin, recombinant human albumin, fetal bovine serum, and other buffer and medium ingredients</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Measles</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Strain</td><td align="center" valign="middle" rowspan="1" colspan="1">Schwarz</td><td align="center" valign="middle" rowspan="1" colspan="1">Enders&#x02019; Edmonston</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strength</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;10<sup>3.0</sup> TCID<sub>50</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;10<sup>3.0</sup> TCID<sub>50</sub></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mumps</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Strain</td><td align="center" valign="middle" rowspan="1" colspan="1">Jeryl Lynn RIT 4385,</td><td align="center" valign="middle" rowspan="1" colspan="1">Jeryl Lynn</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strength </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;10<sup>4.4</sup> TCID<sub>50</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;10<sup>4.3</sup> TCID<sub>50</sub></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"> Rubella</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Strain</td><td align="center" valign="middle" rowspan="1" colspan="1">Wistar RA 27/3</td><td align="center" valign="middle" rowspan="1" colspan="1">Wistar RA 27/3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strength</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;10<sup>3.0</sup> TCID<sub>50</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;10<sup>3.0</sup> TCID<sub>50</sub></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Varicella</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Strain</td><td align="center" valign="middle" rowspan="1" colspan="1">OKA</td><td align="center" valign="middle" rowspan="1" colspan="1">OKA/Merck</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strength</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;10<sup>3.3</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;10<sup>4.0</sup> PFU</td></tr></tbody></table><table-wrap-foot><fn><p>TCID<sub>50</sub>: tissue culture infective dose 50%; PFU: plaque-forming units.</p></fn></table-wrap-foot></table-wrap></floats-group></article>